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Abstract
Forward genetic screens are powerful tools for the unbiased discovery and functional 
characterization of specific genetic elements associated with a phenotype of interest. Recently, the 
RNA-guided endonuclease Cas9 from the microbial CRISPR (clustered regularly interspaced short 
palindromic repeats) immune system has been adapted for genome-scale screening by combining 
Cas9 with pooled guide RNA libraries. Here we describe a protocol for genome-scale knockout 
and transcriptional activation screening using the CRISPR-Cas9 system. Custom- or ready-made 
guide RNA libraries are constructed and packaged into lentiviral vectors for delivery into cells for 
screening. As each screen is unique, we provide guidelines for determining screening parameters 
and maintaining sufficient coverage. To validate candidate genes identified from the screen, we 
further describe strategies for confirming the screening phenotype as well as genetic perturbation 
through analysis of indel rate and transcriptional activation. Beginning with library design, a 
genome-scale screen can be completed in 9–15 weeks followed by 4–5 weeks of validation.
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INTRODUCTION
Systematic and high-throughput genetic perturbation technologies within live model 
organisms are necessary for fully understanding gene function and epigenetic regulation1–3. 
Forward genetic screens allow for a “phenotype-to-genotype” approach to mapping specific 
genetic perturbations to a phenotype of interest. Generally, this involves perturbing many 
genes at once, selecting cells or organisms for a desired phenotype, and then sequencing the 
perturbations to identify the genetic features involved in the phenotypic change. Early 
screening approaches relied on chemical DNA mutagens to induce genetic changes, but this 
process was inefficient and mutations were costly to identify. More recently, tools that utilize 
the RNA interference (RNAi) pathway, specifically short hairpin RNAs (shRNAs)4–7, to 
perturb transcript levels have revolutionized screening approaches8–13. ShRNAs exploit the 
endogenous RNAi machinery to knock down sequence-complementary mRNAs (Fig. 1). 
Despite the contribution of RNAi screens to many biological advances, this approach is 
hampered by incomplete knockdown of transcripts and high off-target activity, resulting in 
low signal-to-noise and limited interpretations14–16.
Cas9 as a tool for precise genome editing
Programmable nucleases have emerged as a promising new genetic perturbation technology 
capable of precisely recognizing and cleaving target DNA17–19. Particularly, the RNA-
guided endonuclease Cas9 from the microbial CRISPR (clustered regularly interspaced short 
palindromic repeat) immune system has proved powerful for precise DNA 
modifications20–25. Cas9 is guided to specific genomic targets by short RNAs that form 
Watson-Crick base pairs with the DNA. Thus Cas9 is easily retargetable.
Cas9 generates precise double-strand breaks (DSBs) at target loci that are repaired through 
either homology-directed repair (HDR) or, more often, non-homologous end-joining 
(NHEJ)26. HDR precisely repairs the DSB using a homologous DNA template, whereas 
NHEJ is error-prone and introduces indels. When Cas9 is targeted to a coding region, loss-
of-function (LOF) mutations can occur as a result of frameshifting indels that produce a 
premature stop codon and subsequent nonsense-mediated decay of the transcript or generate 
a non-functional protein (Fig. 1)24,25. These features make Cas9 ideal for genome editing 
applications.
Transcriptional activation with Cas9
In addition to generating LOF mutations, Cas9 can modulate transcription without 
modifying the genomic sequence through fusing catalytically inactive Cas9 (dCas9) to 
transcriptional activation and repression domains27–34. CRISPR activation (CRISPRa) and 
CRISPR inhibition (CRISPRi) can be achieved by direct fusion or recruitment of activation 
and repression domains, such as VP64 and KRAB, respectively29,35. CRISPRa in particular 
offers a significant improvement as a screening platform over other activation approaches. 
Previously gain-of-function (GOF) screens were primarily limited to cDNA overexpression 
libraries, which suffered from incomplete representation, overexpression beyond 
physiological levels and endogenous regulation, lack of isoform diversity, and high cost of 
construction. CRISPRa overcomes these limitations because it activates gene transcription at 
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the endogenous locus and simply requires the synthesis and cloning of RNA guides, making 
it much more affordable.
The first generation of CRISPRa fused dCas9 to a VP64 or p65 activation domain to 
produce modest transcriptional upregulation, the range of which was not suitable for 
genome-scale screening29,31–33,35. Second generation CRISPRa designs produced more 
robust upregulation by recruiting multiple activation domains to the dCas9 complex. For 
instance, SunTag recruits multiple VP64 activation domains via a repeating peptide array of 
epitopes paired with single-chain variable fragment antibodies28. Another activation method, 
VPR, uses a tandem fusion of three activation domains, VP64, p65, and Rta to dCas9 to 
enhance transcriptional activation27. We devised an alternative approach to CRISPRa that 
involved incorporating MS2 binding loops in the sgRNA backbone to recruit two different 
activation domains, p65 and HSF1, to a dCas9-VP64 fusion (Fig. 1)30. By recruiting three 
distinct transcriptional effectors, this synergistic activation mediator (SAM) complex could 
robustly and reliably drive transcriptional upregulation. A comparison of SunTag, VPR, and 
SAM across various cell types and species suggested that SAM induced more potent 
activation in some contexts, but further analysis is needed to determine which approach is 
most effective for GOF screening36.
Applications of CRISPR-Cas9 screening
Together with large pooled single guide RNA (sgRNA) libraries, Cas9 can mediate high-
throughput LOF and GOF dissection of many selectable phenotypes and elucidate complex 
biological questions. As a proof of principle to demonstrate the CRISPR-Cas9 system’s 
utility for screening, we constructed genome-scale CRISPR-Cas9 knockout (GeCKO) and 
SAM libraries to identify genes that, upon knockout or activation, confer resistance to the 
BRAF-inhibitor vemurafenib in a melanoma cell line30,37. In addition to vemurafenib 
resistance, CRISPR-Cas9 screens have provided insight into the molecular basis of gene 
essentiality, drug and toxin resistance, the hypoxia response, and the role of flavivirus host 
factors in infection28,30,37–52. Although most screens have been performed in in vitro 
systems, the Cas9 system has also been applied ex vivo in dendritic cells to study the 
bacterial lipopolysaccharides response and in vivo to identify key factors that allow a non-
metastatic lung cancer cell line to metastasize42,44. CRISPR-Cas9 screens have also been 
expanded to the noncoding genome through saturated mutagenesis by tiling sgRNAs across 
a noncoding locus to uncover functional elements in the BCL11A enhancer, POU5F1 locus, 
and CUL3 locus, as well as p53 and ESR1 transcription factor binding sites53–57. For 
reference, we have compiled a table of previously published screens (Table 1).
Here we explain in detail how to set up and perform pooled genome-scale knockout and 
transcriptional activation screens using Cas9. We describe protocols for designing and 
cloning an sgRNA library, packaging lentiviral vectors for transduction, analyzing screening 
results, and validating candidate genes identified from the screen (Fig. 2). Although we 
specifically focus on knockout and activation screening using the GeCKO and SAM 
systems, the protocol can be applied to other types of screens (e.g. other CRISPRa systems, 
Cas9 knockdown, and saturated mutagenesis).
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Comparison with other pooled screening technologies
Although both shRNA and Cas9 are easily retargetable, extensive characterization has 
shown that Cas9 is much more robust and specific than shRNA37,58–61. A comparison of 
GeCKO with shRNA screening indicated that for guides targeting the same gene, GeCKO 
results were more consistent and had higher validation rates37. For LOF screening to identify 
essential genes, Cas9 knockout screening has been shown to be more consistent and 
effective than shRNA screening61. Cas9 knockout screening consistently identified more 
lethal genes than shRNA, indicating a lower false negative rate and suggesting that 
identification of cellular dependencies may require complete gene inactivation62.
At the same time, however, in amplified regions of cancer cell genomes, DSBs generated by 
the Cas9 nuclease can produce gene-independent DNA damage phenotypes and false 
positive results45,62,63. Cas9 knockout screens that target the 5′ exons of candidate genes 
may produce in-frame variants that retain functionality and obscure genetic dependencies, a 
limitation that may be overcome by targeting functional protein domains43. Furthermore, 
there is evidence that Cas9 and shRNA screens identify non-overlapping gene sets and may 
have different false positive or false negative results64. While Cas9 knockout screening is an 
enormously valuable LOF screening method, shRNA and CRISPRi screening may 
complement Cas9 knockout screening to further elucidate complex biological questions.
Experimental Design
Screening strategies—In general, there are two formats for conducting a screen: arrayed 
and pooled. For arrayed screens, individual reagents are aliquoted into separate wells in 
multi-well plates. This format allows for a diverse range of measured phenotypes such as 
fluorescence, luminescence, or even direct imaging of cellular phenotypes2,65–67, but it is 
costly and time-consuming. An alternative format, and one that has been widely used for 
Cas9-based screens, is pooled screening in which pooled lentiviral libraries are transduced at 
a low multiplicity of infection (MOI) to ensure that most cells receive only one stably-
integrated RNA guide. After the screen is complete, deep sequencing of the sgRNAs in the 
bulk genomic DNA identifies changes in the sgRNA distribution due to the applied 
screening selection pressure. As a result, pooled screens are less expensive and time-
intensive than arrayed screens, but are generally limited to growth phenotypes or to 
florescence-activated cell sorting (FACS)-selectable phenotypes. These can be categorized as 
positive (e.g. resistance to a drug, toxin, or pathogen), negative (e.g. essential genes, 
toxicity), or marker gene selection (e.g. reporter gene expression) (Box 1).
Regardless of the type of screening selection, NGS is used to compare the number of reads 
for each sgRNA in the perturbed experimental condition relative to a control to identify 
candidate genes for validation. For positive and negative selection screens, the experimental 
and control conditions may be the same infection replicate treated with drug and vehicle 
respectively or analyzed at two different time points. For marker gene selection screens, 
during FACS the cells with the highest and lowest marker gene expressions are selected for 
the experimental and control conditions.
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Design and selection of the sgRNA library: Although each sgRNA library is 
computationally designed for a specific purpose, the basic design process is consistent 
across libraries. First, the genomic regions of interest for targeting the sgRNA library are 
identified based on known sgRNA targeting rules (e.g. 5′ conserved exons for gene 
knockout, upstream or downstream of the transcriptional start site for transcriptional 
activation or repression respectively). Second, all possible sgRNA targets with the Cas9 
ortholog-specific protospacer adjacent motif (PAM) are identified and selected based on four 
criteria: (i) minimization of off-target activity, (ii) maximization of on-target activity, (iii) 
avoidance of homopolymer stretches (e.g. AAAA, GGGG), and (iv) GC content. Recent 
work has begun to elucidate the features that govern sgRNA specificity and efficiency41,47. 
Although specificity and efficiency will likely vary across experimental settings, false 
positive sgRNAs in screens can still be mitigated by including redundant sgRNAs in the 
library and requiring multiple distinct sgRNAs targeting the same gene to display the same 
phenotype when identifying screening hits. Once the targeting sgRNAs have been chosen, 
additional non-targeting guides that do not target the genome should be included as negative 
controls. Non-targeting guides are critical for evaluating the noise and success of a screen. 
At the end of the screen, top hit-targeting guides in the experimental condition should be 
significantly enriched or depleted compared to those in the control condition, while the non-
targeting guides should remain relatively unchanged between experimental and control 
conditions.
We provide several genome-scale libraries for knockout and activation screening through 
Addgene (see REAGENTS). For knockout screening, the GeCKO v2 libraries target the 5′ 
conserved coding exons of 19,050 human or 20,611 mouse coding genes with 6 sgRNAs per 
gene (Fig. 3a)68. In addition to targeting coding genes, the GeCKO v2 libraries also target 
1,864 human miRNAs or 1,175 mouse miRNAs with 4 sgRNAs per miRNA. Each species-
specific library contains 1,000 non-targeting control sgRNAs. The GeCKO library is 
available in a 1 vector (lentiCRISPR v2) or 2 vector (lentiCas9-Blast and lentiGuide-Puro) 
format (Fig. 3b). For activation screening, the SAM libraries target the 200bp region 
upstream of the transcriptional start site of 23,430 human or 23,439 mouse RefSeq coding 
isoforms with 3 sgRNAs per isoform (Fig. 3c)30. The library has to be combined with 
additional SAM effectors in a 2 vector (lentiSAM v2 and lenti MS2-P65-HSF1_Hygro) or 3 
vector (lenti dCAS-VP64_Blast, lenti MS2-P65-HSF1_Hygro, and lenti sgRNA(MS2)_Puro 
or lenti sgRNA(MS2)_Zeo) format (Fig. 3d). Both GeCKO v2 and SAM libraries prioritize 
sgRNAs with minimal off-target activity.
For designing custom libraries, we have provided a python script (Supplementary Data 1) 
that generates sgRNAs targeting a set of genes at specified genomic regions. The script 
prioritizes sgRNAs with fewer potential off-target sites by accounting for position and 
distribution of mismatches between the candidate spacer sequence and similar sites in the 
genome59. One can readily adapt this python script to design libraries for different genomes, 
nucleases, or regions of interest, such as noncoding regions for saturated mutagenesis 
screening or protein functional domains. In cases when a subset of genes is known to be 
involved in the screening phenotype and/or when the cell number is limited, one can 
consider performing a targeted screen that captures a subset of the genes in the genome-scale 
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screens provided. We have included a python script (Supplementary Data 2) for isolating the 
sgRNA target sequences corresponding to the genes in the targeted screen and adding 
flanking sequences for cloning. Additionally, one can consider adapting the sgRNA library 
plasmid backbone to the needs of the screen. For instance, when screening in vivo in 
complex tissues, one can use a cell-type specific promoter to ensure that only the cell type of 
interest is perturbed. To select for successful transduction by FACS, one can replace the 
antibiotic selection marker with a fluorescent marker. For these situations, we provide below 
a protocol for cloning a custom sgRNA library.
Approaches for sgRNA library construction and delivery: Throughout the sgRNA library 
cloning and amplification process, it is important to minimize any potential bias that may 
affect screening results. For example, the number of PCR cycles in the initial amplification 
of the pooled oligo library synthesis should be limited to prevent introducing bias during 
amplification. Scale each step of the cloning procedure provided according to the size of the 
library to reduce loss of sgRNA representation. After sgRNA library transformation, limit 
the growth time to avoid intercolony competition which can result in plasmid amplification 
bias. Here we provide a protocol and accompanying python script (Supplementary Data 3) 
for assessing sgRNA library distribution by next-generation sequencing (NGS) prior to 
screening.
Depending on the desired application, the sgRNA library can be delivered with lentivirus, 
retrovirus, or adeno-associated virus (AAV). Lentivirus and retrovirus integrate into the 
genome, whereas AAV does not integrate and thus for screening, AAV delivery is limited to 
non-dividing cells. In contrast, retrovirus only transduces dividing cells. In addition, AAV 
has a smaller insert size capacity compared to lentivirus and retrovirus. As a result, to date 
most of the screens have relied on lentiviral delivery and we have provided two methods for 
lentivirus production and transduction.
Selection: Since the parameters for each screen differ according to the screening phenotype, 
in lieu of providing a protocol for screening selection we have outlined general 
considerations for setting the relevant screening parameters as well as technical advice for 
carrying out a screening selection in Box 2. Additional in vivo screening considerations are 
described in Box 3. We also provide guidelines for saturated mutagenesis screening design 
and analysis in Box 4.
Analysis of screening results: For examples of anticipated results, we provide data from 
genome-scale knockout and transcriptional activation screening for genes that confer BRAF 
inhibitor vemurafenib (PLX) resistance in a BRAFV600E (A375) cell line30,37. As a result of 
the screening selection pressure, at the end of a successful screen the sgRNA library 
distribution in the experimental condition should be significantly skewed compared to the 
baseline and control conditions, with some sgRNAs enriched and others depleted (as 
assayed by NGS) (Fig. 4a,b). The targeting sgRNA representation should be significantly 
skewed compared to the non-targeting sgRNA representation, which should be relatively 
unchanged. In addition, the relative enrichment or depletion of sgRNAs between the 
experimental and control conditions should correlate between different infection replicates. 
Depending on the type of screen (positive, negative, or marker gene selection), the 
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enrichment or depletion of sgRNAs will be used to identify candidate genes that confer the 
screening phenotype.
Screening analysis methods such as RNAi gene enrichment ranking (RIGER), redundant 
siRNA activity (RSA), Model-based Analysis of Genome-wide CRISPR/Cas9 Knockout 
(MAGeCK), and STARS typically select candidate genes with multiple enriched or depleted 
sgRNAs to reduce the possibility that the observed change in sgRNA distribution was due to 
off-target activity of a single sgRNA47,69–71. RIGER ranks sgRNAs according to their 
enrichment or depletion and for each gene, examines the positions of the sgRNAs targeting 
that gene in the ranked sgRNA list69. The algorithm then assesses whether the set of 
positions is biased towards the top of the list using a Kolmogorov-Smirnov statistic and 
calculates an enrichment score and gene ranking based on a permutation test. RSA is similar 
to RIGER, except that it assigns statistical significance based on an iterative hypergeometric 
distribution formula70. Another screening analysis method, MAGeCK, assesses the 
statistical significance of sgRNA rankings using the negative binomial model before 
identifying positively and negatively selected genes and pathways using the robust ranking 
aggregation algorithm71. STARS scores genes using the probability mass function of a 
binomial distribution and generates false-discovery rates47.
These screening analysis methods can be adapted for noncoding screens by partitioning the 
noncoding region into smaller sections and assigning sgRNAs to each section. Since indels 
can be of varying lengths, sections with consistent enrichment or depletion of multiple 
sgRNAs indicate the presence of a potentially functional regulatory element. In this protocol 
we describe in detail how to identify candidate genes using RIGER. Each candidate gene 
identified from the screening analysis should have multiple significantly enriched or 
depleted sgRNAs in the experimental condition relative to the control (Fig. 4c,d). The 
RIGER P values of the candidate genes should also be significantly lower than the rest of the 
genes (Fig. 4e,f).
Validation of candidate genes: Given that the screening process can be noisy and the 
analysis produces a ranked list of candidate genes, it is necessary to verify that perturbation 
of the identified candidate genes confers the phenotype of interest. For validation, each of 
the sgRNAs that target the candidate gene can be individually cloned into the plasmid 
backbone of the sgRNA library and validated for the screening phenotype. In addition, the 
perturbation induced by each sgRNA, indel rate and transcriptional activation for knockout 
and activation screening, respectively, will be quantified to establish a phenotype-to-
genotype relationship.
Indel rates can be detected either by the SURVEYOR nuclease assay or by NGS. Compared 
to SURVEYOR, which we have described previously72, NGS is more suitable for sampling 
a large number of sgRNA target sites and therefore described here. For measuring indel 
rates, it is important to design primers situated at least 50 bp from the target cleavage site to 
allow for the detection of longer indels. Our protocol for targeted NGS outlines a two-step 
PCR in which the first step uses custom primers to amplify the genomic region of interest 
and the second step uses universal, barcoded primers for multiplex deep sequencing on the 
Illumina platform. Relative to the one-step PCR method recommended for preparing sgRNA 
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libraries for NGS, the two-step PCR method is more versatile and less costly for assessing 
many different target sites because custom primers for each target site can be readily 
combined with different universal, barcoded primers.
After NGS, indel rates can be calculated by running the provided python script 
(Supplementary Data 4) that implements two different algorithms. The first aligns reads 
using the Ratcliff-Obershelp algorithm and then finds regions of insertion or deletion from 
this alignment73. The second method, adapted from the Geneious aligner, scans k-mers 
across the read and maps the alignment to detect indels74. In practice, the Ratcliff-Obershelp 
alignment algorithm is more accurate, while the k-mer based alignment algorithm is faster. 
These indel rates are then adjusted to account for background indel rates via a maximum 
likelihood estimation (MLE) correction59. The MLE correction models the observed indel 
rate as a combination of the true indel rate resulting from Cas9 cleavage and a separately 
measured background indel rate. The true indel rate is that which maximizes the probability 
of the observed read counts under the assumption that they obey a binomial distribution with 
the background rate.
Measurement of transcriptional activation usually entails isolation of RNA, reverse 
transcription of the RNA to cDNA, and quantitative PCR (qPCR). Various different methods 
have been described for each step of the process. In this protocol, we provide a method for 
reverse transcription followed by qPCR that is rapid, high-throughput, and cost-effective and 
thus ideal for quantifying fold upregulation for validation. Our method involves direct lysis 
of cells grown on a 96-well plate followed by reverse transcription and TaqMan qPCR. 
TaqMan-based detection is more specific and reproducible than SYBR-based detection 
because it relies on a fluorogenic probe specific to the target gene, whereas SYBR depends 
on a dsDNA-binding dye. TaqMan also allows for multiplexing with control probes that 
measure housekeeping gene expression as a proxy for total RNA concentration.
After validation of the screening phenotype and perturbation, we recommend verifying 
down- or up-regulation of protein expression for knockout or transcriptional activation 
screening respectively. Immunohistochemistry and Western blot are two of the most 
common methods for verifying protein expression. Immunohistochemistry requires fixing 
the validation cell lines and detecting the target protein using a specific antibody, whereas 
Western blot involves harvesting protein and separating by electrophoresis before staining 
with the specific antibody. Although immunohistochemistry provides additional information 
on protein localization, it often requires a more specific antibody than Western blot because 
proteins are not separated by size. Thus, Western blot is preferable for verifying protein 
expression of candidate genes.
MATERIALS
REAGENTS
SgRNA libraries and backbones
• lentiCRISPR v2 (Addgene, cat. no. 52961)
• lentiCas9-Blast (Addgene, cat. no. 52962)
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• lentiGuide-Puro (Addgene, cat. no. 52963)
• lenti dCAS-VP64_Blast (Addgene, cat. no. 61425)
• lenti MS2-P65-HSF1_Hygro (Addgene, cat. no. 61426)
• lenti sgRNA(MS2)_Zeo backbone (human; Addgene, cat. no. 61427)
• lenti sgRNA(MS2)_Puro backbone (human; Addgene, cat. no. 73795)
• lenti sgRNA(MS2)_Puro optimized backbone (mouse; Addgene, cat. no. 73797)
• lentiSAMv2 backbone (human; Addgene, cat. no. 75112)
• Human GeCKO v2 Library, 1 plasmid system (Addgene, cat. no. 1000000048)
• Human GeCKO v2 Library, 2 plasmid system (Addgene, cat. no. 1000000049)
• Mouse GeCKO v2 Library, 1 plasmid system (Addgene, cat. no. 1000000052)
• Mouse GeCKO v2 Library, 2 plasmid system (Addgene, cat. no. 1000000053)
• Human SAM Library, Zeo, 3 plasmid system (Addgene, cat. no. 1000000057)
• Human SAM Library, Puro, 3 plasmid system (Addgene, cat. no. 1000000074)
• Mouse SAM Library, Puro optimized, 3 plasmid system (Addgene, cat. no. 
1000000075)
• Human SAM library, lentiSAMv2, 2 plasmid system (Addgene, cat. no. 
1000000078)
Custom sgRNA library cloning
• Pooled oligo library (Twist Bioscience or CustomArray)
• PCR primers for amplifying oligo library for cloning are listed in Table 2. 
Primers longer than 60bp can be ordered as 4-nmol ultramers (Integrated DNA 
technologies)
• NEBNext High Fidelity PCR Master Mix, 2× (New England BioLabs, cat. no. 
M0541L) Critical To minimize error in amplifying oligos, it is important to use 
a high-fidelity polymerase. Other high-fidelity polymerases, such as PfuUltra II 
(Agilent) or Kapa HiFi (Kapa Biosystems), may be used as a substitute. For 
amplification of high-diversity libraries such as sgRNA libraries, we recommend 
the NEBNext High-Fidelity PCR Master Mix.
• UltraPure DNase/RNase-free distilled water (Thermo Fisher, cat. no. 10977023)
• QIAquick PCR Purification Kit (Qiagen, cat. no. 28104)
• QIAquick gel extraction kit (Qiagen, cat. no. 28704)
• UltraPure TBE buffer, 10x (Thermo Fisher, cat. no. 15581028)
• SeaKem LE agarose (Lonza, cat. no. 50004)
• SYBR Safe DNA stain, 10,000x (Thermo Fisher, cat. no. S33102)
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• 1-kb Plus DNA ladder (Thermo Fisher, cat. no. 10787018)
• 50bp DNA ladder (Thermo Fisher, cat. no. 10416014)
• TrackIt Cyan/Orange Loading Buffer (Thermo Fisher, cat. no. 10482028)
• FastDigest Esp3I (BsmBI; Thermo Fisher, cat. no. FD0454)
• FastAP Thermosensitive Alkaline Phosphatase (Thermo Fisher, cat. no. EF0651)
• DTT, Molecular Grade (Promega, cat. no. P1171)
• Gibson Assembly Master Mix (New England BioLabs, cat. no. E2611L)
• GlycoBlue Coprecipitant (Thermo Fisher, cat. no. AM9515)
• 2-Propanol (Sigma-Aldrich, cat. no. I9516-25ML)
• Sodium chloride solution (Sigma-Aldrich, cat. no. 71386-1L)
• Tris-EDTA buffer solution (Sigma-Aldrich, cat. no. 93283-100ML)
SgRNA plasmid amplification
• LB Agar, Ready-Made Powder (Affymetrix, cat. no. 75851)
• LB Broth, Ready-Made Powder (Affymetrix, cat. no. 75852)
• Ampicillin, 100 mg ml−1, sterile filtered (Sigma-Aldrich, cat. no. A5354)
• Endura ElectroCompetent Cells (Lucigen, cat. no. 60242) Critical High 
efficiency competent cells (>1010 cfu μg−1) reduce the number of 
electroporations required for obtaining sufficient sgRNA library representation.
• NucleoBond Xtra Maxi EF (Macherey-Nagel, cat. no. 740424.10) Critical An 
endotoxin-free plasmid purification kit is important for avoiding endotoxicity in 
virus production and mammalian cell culture. Other endotoxin-free plasmid 
purification kits, such as the Qiagen Plasmid Plus Midi kit, may be used as 
substitutes.
• One Shot Stbl3 chemically competent E. coli (Thermo Fisher, cat. no. C737303)
• SOC outgrowth medium (New England BioLabs, cat. no. B9020S)
• NucleoBond Xtra Midi EF (Macherey-Nagel, cat. no. 740420.50) Critical An 
endotoxin-free plasmid purification kit is important for avoiding endotoxicity in 
virus production and mammalian cell culture. Other endotoxin-free plasmid 
purification kits, such as the Qiagen Plasmid Plus Maxi kit, may be used as 
substitutes.
Next-generation sequencing
• Primers for amplifying the library for NGS are listed in Table 3. Primers for 
amplifying indels for NGS are listed in Table 4. Primers longer than 60bp can be 
ordered as 4 nmol ultramers (Integrated DNA technologies)
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• KAPA HiFi HotStart ReadyMix, 2× (Kapa Biosystems, cat. no. KK2602) 
Critical To minimize error in amplifying oligos, it is important to use a high-
fidelity polymerase. Other high-fidelity polymerases, such as PfuUltra II 
(Agilent) or Kapa HiFi (Kapa Biosystems), may be used as a substitute. For 
amplification of gDNA for indel analysis, we recommend the KAPA HiFi 
HotStart ReadyMix.
• Qubit dsDNA HS Assay Kit (Thermo Fisher, cat. no. Q32851)
• NextSeq 500/550 High Output Kit v2 (150 cycle; Illumina, cat. no. 
FC-404-2002)
• MiSeq Reagent Kit v3 (150 cycle; Illumina, cat. no. MS-102-3001)
• MiSeq Reagent Kit v2 (300 cycle; Illumina, cat. no. MS-102-2002)
• PhiX Control Kit v3 (Illumina, cat. no. FC-110-3001)
• Sodium hydroxide solution, 10 N (Sigma-Aldrich, cat. no. 72068-100ML) 
Caution Sodium hydroxide, 10 N is very hazardous in case of contact with skin, 
contact with eyes, ingestion, and inhalation. Wear protective clothing and avoid 
contact.
• Tris, pH 7.0 (Thermo Fisher, cat. no. AM9850G)
Mammalian cell culture
• HEK293FT (Thermo Fisher, cat. no. R70007) Caution Check cell lines regularly 
to ensure they are authentic and are not infected with mycoplasma.
• DMEM, high glucose, GlutaMAX Supplement, pyruvate (Thermo Fisher, cat. 
no. 10569010)
• Penicillin-streptomycin, 100× (Thermo Fisher, cat. no. 15140122)
• Fetal bovine serum, premium grade (VWR, cat. no. 97068-085)
• TrypLE Express, no phenol red (Thermo Fisher, cat. no. 12604021)
• HUES 66 cell line (Harvard Stem Cell Science) Caution Check cell lines 
regularly to ensure they are authentic and are not infected with mycoplasma.
• Geltrex LDEV-free reduced growth factor basement membrane matrix (Thermo 
Fisher, cat. no. A1413202)
• mTeSR1 medium (Stemcell Technologies, cat. no. 05850)
• Normocin (InvivoGen, cat. no. ant-nr-1)
• Rho-associated protein kinase (ROCK) inhibitor (Y-27632; Millipore, cat. no. 
SCM075)
• Accutase (Stemcell Technologies, cat. no. 07920)
• Dulbecco’s PBS (DPBS; Thermo Fisher, cat. no. 14190250)
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Lentivirus production and titer
• Opti-MEM I reduced serum medium (Thermo Fisher, cat. no. 31985062)
• pMD2.G (Addgene, cat. no. 12259)
• psPAX2 (Addgene, cat. no. 12260)
• pcDNA3-EGFP transfection control plasmid (Addgene, cat. no. 13031)
• Lipofectamine 2000 transfection reagent (Thermo Fisher, cat. no. 11668019)
• PLUS Reagent (Thermo Fisher, cat. no. 11514015)
• Polyethylenimine HCl MAX, Linear, Mw 40,000 (PEI Max; Polysciences, cat. 
no. 24765-1)
• Polybrene (Hexadimethrine bromide; Sigma-Aldrich, cat. no. 107689-10G)
• Blasticidin S HCl (Thermo Fisher, cat. no. A1113903)
• Puromycin dihydrochloride (Thermo Fisher, cat. no. A1113803)
• Hygromycin B (Thermo Fisher, cat. no. 10687010)
• Zeocin (Thermo Fisher, cat. no. R25001)
• CellTiter-Glo Luminescent Cell Viability Assay (Promega, cat. no. G7571)
Screening and Validation
• Quick-gDNA MidiPrep (Zymo Research, cat. no. D3100)
• DNA Binding Buffer (Zymo Research, cat. no. D4004-1-L)
• DNA Wash Buffer (Zymo Research, cat. no. D4003-2-24)
• DNA Elution Buffer (Zymo Research, cat. no. D3004-4-4)
• Ethyl alcohol, Pure (Sigma-Aldrich, cat. no. 459844-500ML)
• Primers for cloning the validation sgRNAs are listed in Table 5. (Integrated DNA 
technologies)
• T4 polynucleotide kinase (New England BioLabs, cat. no. M0201S)
• T4 DNA ligase reaction buffer, 10× (New England BioLabs, cat. no. B0202S)
• T7 DNA ligase with 2× rapid ligation buffer (Enzymatics, cat. no. L6020L)
• BSA, Molecular Biology Grade (New England BioLabs, cat. no. B9000S)
• QuickExtract DNA extraction solution (Epicentre, cat. no. QE09050)
• RNase AWAY (VWR, cat. no. 53225-514)
• Proteinase K (Sigma-Aldrich, cat. no. P2308-25MG)
• Tris, 1 M, pH 8.0 (Thermo Fisher, cat. no. AM9855G)
• Deoxyribonuclease I bovine (Sigma-Aldrich, cat. no. D2821-50KU)
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• UltraPure 1 M Tris-HCI Buffer, pH 7.5 (Thermo Fisher, cat. no. 15567027)
• Calcium chloride solution (Sigma-Aldrich, cat. no. 21115-1ML)
• Glycerol (Sigma-Aldrich, cat. no. G5516-100ML)
• MgCl2, 1 M (Thermo Fisher, cat. no. AM9530G)
• Triton X-114 (Sigma-Aldrich, cat. no. X114-100ML)
• Proteinase K Inhibitor (EMD Millipore, cat. no. 539470-10MG)
• Dimethyl sulfoxide (Sigma-Aldrich, cat. no. D8418-50ML)
• Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (Sigma-
Aldrich, cat. no. E3889-10G)
• RevertAid RT Reverse Transcription kit (Thermo Fisher, cat. no. K1691)
• Oligo dT (TTTTTTTTTTTTTTTTTTTTNN; Integrated DNA Technologies)
• TaqMan target probes, FAM dye (Thermo Fisher)
• Taqman endogenous control probe, VIC dye (e.g. Human GAPD, GAPDH, 
Endogenous Control VIC®/MGB probe, primer limited; Thermo Fisher, cat. no. 
4326317E)
• TaqMan Fast Advanced Master Mix, 2x (Thermo Fisher, cat. no. 4444557)
EQUIPMENT
• Axygen 8-Strip PCR tubes (Fisher Scientific, cat. no. 14-222-250)
• Axygen PCR plates, 96 well (VWR, cat. no. PCR-96M2-HS-C)
• 384-well optical plate (e.g. Roche, LightCycler 480 Multiwell plate 384, cat. no. 
5102430001)
• Axygen 1.5 ml Boil-Proof Microcentrifuge Tubes, (VWR, cat. no. 10011-702)
• Falcon tubes, polypropylene, 15 ml (Corning cat. no. 352097)
• Falcon tubes, polypropylene, 50 ml (Corning, cat. no. 352070)
• Filtered sterile pipette tips (e.g. Rainin)
• 100 mm × 15 mm Not TC-Treated Bacteriological Petri Dish (Corning, cat. no. 
351029)
• 245mm Square BioAssay Dish without Handles, not TC-Treated Culture 
(Corning, cat. no. 431111)
• VWR Bacti Cell Spreaders (VWR, cat. no. 60828-688)
• AirPore Tape Sheets (Qiagen, cat. no. 19571)
• Nunc EasYFlask 25cm2, Filter Cap, 7 ml working volume (T25 flask; Thermo 
Scientific, cat. no. 156367)
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• Nunc EasYFlask 75cm2, Filter Cap, 25 ml working volume, (T75 flask; Thermo 
Scientific, cat. no. 156499)
• Nunc EasYFlask 225 cm2, filter cap, 70 ml working volume (T225 flask; 
Thermo Scientific, cat. no. 159934)
• Corning bottle-top vacuum filter system, 0.22 μM (Sigma-Aldrich, cat. no. 
CLS431098)
• Stericup filter unit, 0.45 μM (Millipore, cat. no. SCHVU02RE)
• Syringe filter unit, 0.45 μM (Millipore, cat. no. SLHV013SL)
• Disposable Syringes with Luer-Lok Tip (Fisher Scientific, cat. no. 14-829-45)
• Falcon tissue culture plate, 6 wells (Corning, cat. no. 353224)
• Falcon tissue culture plate, 12 wells (Corning, cat. no. 353043)
• Falcon tissue culture dish, 100mm (Corning, cat. no. 353003)
• 96 well flat clear bottom black polystyrene TC-treated microplates (Corning, cat. 
no. 3904)
• BD BioCoat clear Poly-D-Lysine 96 well clear flat bottom TC-treated microplate 
(Corning, cat. no. 356461)
• Cellometer SD100 Counting Chambers (Nexcelom Bioscience, cat. no. CHT4-
SD100-002)
• Zymo-Spin V with Reservoir (Zymo Research, cat. no. C1016-25)
• Collection Tubes, 2 ml (Zymo Research, cat. no. C1001-25)
• Amicon Ultra-15 Centrifugal Filter Unit with Ultracel-100 membrane (Millipore, 
cat. no. UFC910008)
• Thermocycler with programmable temperature stepping functionality, 96 well 
(e.g. Applied Biosystems Veriti, cat. no. 4375786)
• Real-time PCR system, 384 well (e.g. Roche Lightcycler 480 cat. no. 
05015243001)
• Desktop microcentrifuges (e.g. Eppendorf, cat. nos. 5424 and 5804)
• Eppendorf ThermoStat C (Eppendorf, cat. no. 5383000019)
• Gene Pulser Xcell Microbial System (Bio-Rad, cat. no. 1652662)
• Digital gel imaging system (GelDoc EZ, Bio-Rad, cat. no. 170-8270), and blue 
sample tray (Bio-Rad, cat. no. 170-8273)
• Blue-light transilluminator and orange filter goggles (SafeImager 2.0; Invitrogen, 
cat. no. G6600)
• Gel quantification software (Bio-Rad, ImageLab or open-source ImageJ frmo the 
National Institutes of Health (NIH), USA, available at http://rsbweb.nih.gov/ij/)
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• UV spectrophotometer (e.g. NanoDrop 2000c, Thermo Scientific)
• Plate spectrophotometer (e.g. Synergy H4 Hybrid Multi-Mode Microplate 
Reader, BioTek)
• Qubit Assay Tubes (Thermo Fisher, cat. no. Q32856)
• Qubit Fluorometer (Thermo Fisher, cat. no. Q33216)
• MiSeq System (Illumina, cat. no. SY-410-1003)
• NextSeq 500/550 System (Illumina, cat. nos. SY-415-1001 and SY-415-1002)
• Cell counter (e.g. Cellometer Image Cytometer, Nexcelom Bioscience)
• Sorvall Legend XTR Centrifuge (Thermo Fisher, cat. no. 75004520)
• Python 2.7 (https://www.python.org/downloads/)
• Twobitreader (https://pypi.python.org/pypi/twobitreader)
• Biopython (http://biopython.org/DIST/docs/install/Installation.html)
• Seqmap (http://www-personal.umich.edu/~jianghui/seqmap/)
REAGENT SETUP
TBE electrophoresis solution—Dilute TBE buffer in distilled water to a 1× working 
condition, and store it at room temperature (18–22 °C) for up to 6 months.
Ethanol, 80% (vol/vol)—Prepare 80% (vol/vol) ethanol in UltraPure water right before 
use.
D10 medium—For culture of HEK 293FT cells, prepare D10 medium by supplementing 
DMEM with GlutaMAX and 10% (vol/vol) FBS. For routine cell line culture and 
maintenance, D10 can be further supplemented with 1× penicillin-streptomycin. Store the 
medium at 4 °C for up to 1 month.
mTeSR1 medium—For culture of human embryonic stem cells (hESCs), prepare mTeSR1 
medium by supplementing it with the supplement supplied with the medium and 100 μg 
ml−1 Normocin. Prepared medium can be stored at 4 °C for up to 2 months.
Proteinase K, 300 U ml−1—Resuspend 25 mg of Proteinase K in 2.5 ml of 10 mM Tris, 
pH 8.0 for 10 mg ml−1 (300 U ml−1) of Proteinase K. Store at 4 °C for up to 1 year.
Deoxyribonuclease I, 50 KU ml−1—Resuspend 50 KU of Deoxyribonuclease I in a 
solution containing 50% (vol/vol) Glycerol, 10 mM CaCl2, and 50 mM Tris-HCl (pH 7.5) 
for 50 KU ml−1 of Deoxyribonuclease I; as follows. Store at −20 °C for up to 2 years.
Component Amount (μl) Final concentration
Tris-HCl, pH 7.5, 1M 250 50 mM
CaCl2, 1M 50 10 mM
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Glycerol 2500 50% (vol/vol)
UltraPure Water 2200
Total 5000
RNA lysis buffer—Prepare a solution with 9.6 mM Tris-HCl (pH 7.8), 0.5 mM MgCl2, 
0.44 mM CaCl2, 10 μM DTT, 0.1% (wt/vol) Triton X-114, and 3 U ml−1 Proteinase K in 
UltraPure water, as follows. The final pH of the solution should be approximately 7.8. Store 
at 4 °C for up to 1 year. Critical Prepare solution under RNAse-free conditions.
Component Amount (ml) Final concentration
Tris, pH 8.0, 1M 1.2 4.8 mM
Tris, pH 7.5, 1M 1.2 4.8 mM
MgCl2, 1M 0.125 0.5 mM
CaCl2, 1M 0.110 0.44 mM
Dtt, 0.1M 0.025 10 μM
Proteinase K, 300 U ml−1 2.5 3 U ml−1
Triton X-114, 10% wt/vol 2.5 0.1% (wt/vol)
UltraPure Water 242
Total 250
EGTA, 0.5 M, pH 8.3—Resuspend EGTA in UltraPure water and adjust the pH of the 
solution to 8.3 with NaOH, 10 N, as follows. Critical EGTA is light sensitive, and can be 
stored at 4 °C protected from light for up to 2 years. Prepare solution under RNAse-free 
conditions. Take aliquots to measure pH in order to keep main stock from being RNAse-
contaminated by the pH probe.
Component Amount Final Concentration
EGTA 9.5 g 0.5 M
Tris, pH 8.0, 1M 3.125 ml 0.0625 M
NaOH, 10N 6.1 ml 1.22 M
UltraPure Water to 50 ml
Total 50 ml
RNA lysis stop solution—Resuspend 10 mg of Proteinase K Inhibitor in 150 μl of 
DMSO for a final concentration of 100 mM. Combine with EGTA, 0.5 M, pH 8.3 for a final 
solution with 1 mM Proteinase K inhibitor, 90 mM EGTA, and 113 μM DTT in UltraPure 
water, as follows. Aliquot into 8-strip PCR tubes to avoid freeze-thaw and facilitate sample 
processing with multichannel pipettes. Store at −20 °C for up to 1 year. Critical Prepare 
solution under RNAse-free conditions.
Component Amount (ml) Final Concentration
Proteinase K inhibitor, 100 mM 0.150 1 mM
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EGTA, 0.5 M, pH 8.3 2.694 90 mM
Dtt, 0.1 M 0.017 113 μM
UltraPure Water 12.14
Total 15
Oligo dT, 100 μM—Resuspend oligo dT to 100 μM in UltraPure water. Aliquot and store 
at −20 °C for up to 2 years.
EQUIPMENT SETUP
Large LB agar plates (245 mm square bioassay dish, ampicillin)—Reconstitute 
the LB Broth with agar at a concentration of 35 g L−1 in deionized water and swirl to mix. 
Autoclave to sterilize. Allow the LB agar to cool to 55 °C before adding ampicillin to a final 
concentration of 100 μg ml−1 and swirl to mix. On a sterile bench area, pour ~300 ml of LB 
agar per 245 mm square bioassay dish. Place the lids on the plates and allow them to cool 
for 30–60 min until solidified. Invert the plates and let sit for several more hours or 
overnight. Agar plates can be stored in plastic bags or sealed with parafilm at 4 °C for up to 
3 months.
Standard LB agar plates (100 mm Petri dish, ampicillin)—Preparation of standard 
LB agar plates is similar to large LB agar plates, except pour ~20 ml of LB agar per 100 mm 
Petri dish. Store at 4 °C for up to 3 months.
PROCEDURE
Designing a custom sgRNA library o TIMING 3–5 w; 1 w hands-on
1 Construct a pooled sgRNA library by designing and cloning a custom sgRNA 
library (Steps 1–17) or amplifying a ready-made library from Addgene (Skip to 
Step 18). We have provided python scripts for designing a library that targets 
any set of genomic coordinates (option A, Supplementary Data 1) or a subset of 
an existing library (option B, Supplementary Data 2).
A. Generation of a library targeting a custom set of genomic coordinates
i. Install requirements for library generation python script. The 
python script design_library.py generates sgRNAs that target 
a set of specified genomic coordinates (Supplementary Data 
1). Install python 2.7, twobitreader, biopython, and seqmap. 
For seqmap, install the version 1.0.13 source code for all 
platforms and compile with g++ -O3 -m64 -o seqmap 
match.cpp. Place seqmap in the same folder as the python 
script design_library.py.
ii. Input target genomic coordinates for library design. Once a 
set of genes and coordinates for the custom sgRNA library 
has been identified, prepare a target genes csv file containing 
the gene name, chromosome, start of the targeted region, and 
end of the targeted region in each column from left to right. 
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The target genes csv file should contain the headers name, 
chrom, start, and end. The python script provided will identify 
potential sgRNAs that target each gene within the genomic 
region as described in the target genes csv file. Refer to the 
table below for a sample input file:
name chrom start end
EGFR chr7 55086525 55086725
LPAR5 chr12 6745297 6745497
GPR35 chr2 241544625 241544825
iii. Design custom library. Download the genome 2bit file that the 
target gene coordinates corresponds to from the UCSC 
Genome Browser (http://hgdownload.cse.ucsc.edu/
downloads.html). The genome 2bit file will be used to 
construct a database of off-target scores based on the position 
and distribution of mismatches between each spacer sequence 
and similar sequences in the genome. For each region in the 
target genes csv file, the python script will identify potential 
sgRNAs and select a specified number of sgRNAs with fewer 
potential off-target sites using this database for the custom 
library. To design a custom library, run python 
design_library.py with the following optional parameters:
Flag Description Default
-o Output csv file with names for target 
genes, spacer sequences, spacer 
orientations, chromosome locations, 
cleavage site locations, off-target scores, 
and oligo library sequences in columns 
from left to right
final_guides.csv
-i Prefix of input genome 2bit file hg19
-g Target genes csv file with the gene name, 
chromosome, start of the targeted region, 
and end of the targeted region in columns 
from left to right
genes.csv
-gc Minimum GC content required for an 
sgRNA spacer sequence
25
-s Minimum spacing required between 
cleavage sites of sgRNAs targeting the 
same genomic region
20
-n Maximum number of guides selected 
targeting each gene in the target genes 
csv file
3
-db Use an existing off-target database 
constructed from a previous custom 
library design for a new library
False
-gecko or -sam Specify the type of library and add the 
respective flanking sequences to the 
spacers for the oligo library synthesis
Neither
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When designing sgRNAs against large genomic regions 
(>50kb), we recommend splitting the target genes csv file into 
several files containing different subsets of the target genes to 
parallelize the library design process and minimize run time. 
After running design_library.py, the spacers that target the 
specified genomic coordinates will be written to an output csv 
file. When designing a new custom library targeting the same 
genomic regions as a previous custom library, using the 
previously constructed off-target database can significantly 
reduce the script execution time. If -gecko or -sam is 
specified, the full oligo library sequence containing the 
spacers and respective flanking sequences for synthesis will 
be in the last column.
B. Generation of a targeted library from an existing library
i. Input target genes for library design. The python script 
design_targeted_library.py (Supplementary Data 2) extracts 
the sgRNA spacers from an existing library that target a 
specified set of genes. Install python 2.7 (https://
www.python.org/downloads/). Once a set of genes for the 
targeted screen has been identified, prepare a csv file 
containing the names of the target genes with each line 
corresponding to one gene. Prepare another csv file for the 
annotated genome-scale library with the names of each gene 
in the first column and respective spacer sequences in the 
second column. Each line contains a different spacer 
sequence. The gene names in the target genes file should be in 
the same format as the names of the annotated library file.
ii. Design targeted custom library. Isolate the subset of spacers 
from the genome-scale library that correspond to the target 
genes by running python design_targeted_library.py with the 
following optional parameters:
Flag Description Default
-o Output csv file with names for target 
genes, corresponding spacer 
sequences, and oligo library 
sequences in columns from left to 
right
oligos.csv
-l Annotated library csv file with 
names in the first column and 
corresponding spacer sequences in 
the second column
annotated_library.csv
-g Target genes csv file with names of 
target genes
target_genes.csv
-gecko or -sam Specify the type of library and add 
the respective flanking sequences to 
the spacers for the oligo library 
synthesis
Neither
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After running design_targeted_library.py, the subset of 
spacers for the target genes will be written to an output csv 
file. If -gecko or -sam is specified, the full oligo library 
sequence containing the spacers and respective flanking 
sequences for synthesis will be in the last column.
2 Synthesize the oligo library as a pool on an array through a DNA synthesis 
platform such as Twist Bioscience or CustomArray. Synthesis typically requires 
2–4 weeks depending on the size of the oligo library. Parafilm and store pooled 
oligos at −20 °C.
Cloning a custom sgRNA library o TIMING 2 d
3 PCR amplification of pooled oligo library. Throughout the sgRNA library 
cloning process, refer to the following table or the number of reactions 
recommended at each cloning step for a library size of 100,000 sgRNAs and 
scale the number of reactions according to the size of the custom sgRNA library:
Steps Cloning process Number of reactions
3–7 PCR amplification of pooled oligo library 12
8–10 Restriction digest of plasmid backbone 16
11–12 Gibson assembly 10 with sgRNA insert, 5 control
13–17 Isopropanol precipitation 10 with sgRNA insert, 5 control
Amplify the pooled oligo library from Step 2 using the Oligo-Fwd and Oligo-
Rev primers (Table 2). Prepare a master mix using the reaction ratios outlined 
below:
Component Amount per reaction (μl) Final concentration
NEBNext High Fidelity PCR Master Mix, 2× 12.5 1×
Pooled oligo library template from Step 2 1 0.04 ng μl−1
Oligo-Fwd primer (Universal) 1.25 0.5 μM
Oligo-Knockout-Rev or Oligo-Activation-Rev primer 1.25 0.5 μM
UltraPure water 9
Total 25
Critical Step To minimize error in amplifying oligos, it is important to use a 
high-fidelity polymerase. Other high-fidelity polymerases, such as PfuUltra II 
(Agilent) or Kapa HiFi (Kapa Biosystems), may be used as a substitute.
4 Aliquot the PCR master mix into 25 μl reactions and perform a PCR using the 
following cycling conditions:
Cycle number Denature Anneal Extend
1 98 °C, 30 s
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2–21 98 °C, 10 s 63 °C, 10 s 72 °C, 15 s
22 72 °C, 2 min
Critical Step Limit the number of PCR cycles to 20 cycles during amplification 
to reduce potential biases introduced during amplification.
5 After the reaction is complete, pool the PCR reactions and purify the PCR 
product using the QIAquick PCR purification kit according to the 
manufacturer’s directions. Quantify the product by NanoDrop.
6 Run the PCR purified oligo library from Step 5 on a gel along with a 50bp 
ladder: cast a 2% (wt/vol) agarose gel in TBE buffer with SYBR Safe dye. Run 
half of the oligo library in the gel at 15 V cm−1 for 45 min.
Critical Step Run on a 2% (wt/vol) agarose gel for long enough to separate the 
target library (140bp) from a possible primer dimer of ~120bp. Under the 
optimized PCR conditions suggested above the presence of primer dimers 
should be minimal.
7 Gel extract the purified PCR product using the QIAquick gel extraction kit 
according to the manufacturer’s directions and quantify the final product by 
NanoDrop.
8 Restriction digest of plasmid backbone. Digest the desired library plasmid 
backbone with the restriction enzyme Esp3I (BsmBI) that cuts around the 
sgRNA target region. Refer to the master mix set up below for the reaction 
ratios:
Component Amount per reaction (μl) Final concentration
FastDigest Buffer, 10× 2 1×
Library Plasmid Backbone 1 50 ng μl−1
FastDigest Esp3I (BsmBI) 1
FastAP Thermosensitive Alkaline Phosphatase 1
DTT, 100 mM 0.2 1 mM
UltraPure water 14.8
Total 20
9 Aliquot 20 μl reactions from the master mix and incubate the restriction digest 
reaction at 37 °C for 1 h.
10 After the reaction has completed, pool the restriction digest reactions from Step 
9 and run the entire pooled restriction digest reaction on a gel. Cast a 2% (wt/
vol) agarose gel in TBE buffer with SYBR Safe dye and run the reaction in the 
gel at 15 V cm−1 for 30 min. Gel extract the library plasmid backbone using the 
QIAquick gel extraction kit according to the manufacturer’s protocol and 
quantify by NanoDrop. Note that the Gecko library backbones contain a 1880bp 
filler sequence which should be visible as a dropout. The SAM library 
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backbones do not contain a filler sequence and the expected dropout of 20bp is 
usually not readily visible.
11 Gibson Assembly. Set up a master mix for the Gibson reactions on ice according 
to the reaction ratios below. Be sure to include reactions without the sgRNA 
library insert as a control.
Component Amount per reaction Final concentration
Gibson Assembly Master Mix, 2× 10 μl 1×
Digested library Plasmid Backbone from Step 10 330 ng 16.5 ng μl−1
SgRNA library insert from Step 7 or UltraPure water 
control
50 ng 2.5 ng μl−1
UltraPure water To 20 μl
Total 20 μl
12 Aliquot 20 μl reactions from the master mix and incubate the Gibson reaction at 
50 °C for 1h.
Pause Point Completed Gibson reactions can be stored at −20 °C for at least 1 
week.
13 Isopropanol precipitation. Pool cloning and control reactions separately. Purify 
and concentrate the sgRNA library by mixing the following:
Component Amount per reaction (μl) Final concentration
Gibson Assembly Reaction 20
Isopropanol 20
GlycoBlue Coprecipitant 0.2 0.075 μg μl−1
NaCl solution, 5 M 0.4 50 mM
Total ~40
Critical Step In addition to concentrating the library, purification by 
isopropanol precipitation removes salts from the Gibson reaction that can 
interfere with electroporation.
14 Vortex and incubate at room temperature for 15 min and centrifuge at >15,000 × 
g for 15 min to precipitate the plasmid DNA. The precipitated plasmid DNA 
should appear as a small light blue pellet at the bottom of the microcentrifuge 
tube.
15 Aspirate the supernatant and gently wash the pellet twice without disturbing it 
using 1 ml of ice-cold (−20 °C) 80% (vol/vol) ethanol in UltraPure water.
16 Carefully remove any residual ethanol and air dry for 1 min.
17 Resuspend the plasmid DNA pellet in 5 μl of TE per Gibson reaction by 
incubating at 55 °C for 10 min and quantify the custom sgRNA library by 
NanoDrop. Isopropanol-purified sgRNA libraries can be stored at −20 °C for 
several months.
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Amplification of pooled sgRNA library o TIMING 2 d
18 Pooled sgRNA library transformation. Electroporate the library at 50–100 ng 
μl−1 using Endura ElectroCompetent cells according to the manufacturer’s 
directions. If amplifying a ready-made genome-scale library from Addgene, 
repeat for a total of 1 electroporation per 10,000 sgRNAs in the library. If 
amplifying a custom sgRNA library, repeat for a total of 1 electroporation per 
5,000 sgRNAs in the library and include an additional electroporation for the 
control Gibson reaction.
19 Pre-warm 1 large LB agar plate (245 mm square bioassay dish, ampicillin) per 
electroporation of the sgRNA library at 37 °C. Each large LB agar plate can be 
substituted with 10 standard LB agar plates. Pre-warm 1 standard LB agar plate 
(100 mm Petri dish, ampicillin) for calculating electroporation efficiency at 
37 °C. For amplification of a custom sgRNA library, include an additional 
standard LB agar plate for the control Gibson reaction.
20 After the 1 h recovery period, pool electroporated cells and mix well by 
inverting.
21 Prepare a dilution for calculating transformation efficiency. To prepare the 
dilution mix, add 10 μl of the pooled electroporated cells to 990 μl of LB 
medium for a 100-fold dilution and mix well. Then add 100 μl of the 100-fold 
dilution to 900 μl of LB medium for a 1,000-fold dilution and mix well.
22 Plate 100 μl of the 1,000-fold dilution onto a pre-warmed standard LB agar plate 
(100 mm Petri dish, ampicillin from Step 19). This is a 10,000-fold dilution of 
the full transformation that will be used to estimate the transformation 
efficiency.
23 If amplifying a custom sgRNA library, repeat Steps 21–22 for the control 
Gibson reaction.
24 To plate pooled electroporated cells, add 1 volume of LB medium to the pooled 
electroporated cells from Step 20, mix well, and plate on large LB agar plates 
(option A) or standard LB agar plates (option B).
A. Plating on large LB agar plates
i. Plate 2 ml of electroporated cells on each of the pre-warmed 
large LB agar plates from Step 19 using a cell spreader. 
Spread the liquid culture until it is largely absorbed into the 
agar and does not drip when the plate is inverted. At the same 
time, make sure the liquid culture does not completely dry out 
as this will lead to poor survival.
B. Plating on standard LB agar plates
i. Alternatively, plate 200 μl of electroporated cells on each of 
the pre-warmed standard LB agar plates from Step 19 using 
the same technique as described in Step 24 Ai.
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Critical Step Plating the electroporated cells evenly is 
important for preventing intercolony competition that may 
skew the sgRNA library distribution.
25 Incubate all LB agar plates overnight at 37 °C for 12–14 h.
Critical Step Limiting the bacterial growth time to 12–14 h ensures that there is 
sufficient growth for sgRNA library amplification without potentially biasing the 
sgRNA library distribution through intercolony competition or differences in 
colony growth rates.
26 Calculate electroporation efficiency. Count the number of colonies on the 
10,000-fold dilution plate. Multiply the number of colonies by 10,000 and the 
number of electroporations to obtain the total number of colonies on all plates. If 
amplifying a ready-made sgRNA library from Addgene, proceed only if the total 
number of colonies is greater than 100 colonies per sgRNA in the library. If 
amplifying a custom sgRNA library, proceed only if there are more than 500 
colonies per sgRNA in the library.
Critical Step Obtaining a sufficient number of colonies per sgRNA is crucial for 
ensuring that the full library representation is preserved and that sgRNAs did not 
drop out during amplification.
Troubleshooting
27 In addition, for amplification of a custom sgRNA library, calculate the 
electroporation efficiency for the control Gibson reaction and proceed only if 
there are at least 20 times more colonies per electroporation in the sgRNA 
library condition compared to the control Gibson reaction.
Troubleshooting
28 Harvest colonies from the LB agar plates. Pipette 10 ml of LB medium onto 
each large LB agar plate or 1 ml of LB medium onto each standard LB agar 
plate. Gently scrape the colonies off with a cell spreader and transfer the liquid 
with scraped colonies into a 50-ml Falcon tube.
29 For each LB agar plate, repeat Step 28 for a total of 2 LB medium washes to 
capture any remaining bacteria.
30 Calculate the number of maxipreps needed by measuring the OD600 of the 
harvested bacterial suspension as follows: Number of maxipreps = OD600*(total 
volume of suspension)/1200. Maxiprep the amplified sgRNA library by using 
the Macherey-Nagel NucleoBond Xtra Maxi EF kit according to the 
manufacturer’s directions.
Critical Step Using an endotoxin-free plasmid purification kit is important for 
avoiding endotoxicity in virus production and mammalian cell culture. To ensure 
that the plasmid preparation is endotoxin-free, it is important to dilute the 
bacterial suspension to an OD600 within the linear range of the 
spectrophotometer, typically around 0.1–0.5, and measure the OD600 of the 
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dilution. Then multiply the OD600 by the dilution factor to obtain the OD600 of 
the bacterial suspension. Approximately 1 maxiprep is needed for 2 densely 
plated large LB agar plates.
31 Pool the resulting plasmid DNA and quantify by NanoDrop. Maxiprepped 
sgRNA library can be aliquoted and stored at −20 °C.
Next-generation sequencing of the amplified sgRNA library to determine 
sgRNA distribution o TIMING 3–5 d
32 Library PCR for NGS. We have provided NGS primers that amplify the sgRNA 
target region with Illumina adapter sequences (Table 3). To prepare the sgRNA 
library for NGS, set up a reaction for each of the 10 NGS-Lib-Fwd primers and 
1 NGS-Lib-KO-Rev or NGS-Lib-SAM-Rev barcode primer as follows:
Component Amount per 
reaction (μl)
Final concentration
NEBNext High Fidelity PCR Master Mix, 2× 25 1×
Pooled sgRNA library template from Step 31 1 0.4 ng μl−1
NGS-Lib-Fwd primer (unique) 1.25 0.25 μM
NGS-Lib-KO-Rev or NGS-Lib-SAM-Rev primer (barcode) 1.25 0.25 μM
UltraPure water 21.5
Total 50
Critical step Using a different reverse primer with a unique barcode for each 
library allows for pooling and sequencing of different libraries in a single 
NextSeq or HiSeq run. This is more efficient and cost-effective than running the 
same number of libraries on multiple Miseq runs.
Critical Step To minimize error in amplifying sgRNAs, it is important to use a 
high-fidelity polymerase. Other high-fidelity polymerases, such as PfuUltra II 
(Agilent) or Kapa HiFi (Kapa Biosystems), may be used as a substitute.
33 Perform a PCR using the following cycling conditions:
Cycle number Denature Anneal Extend
1 95 °C, 5 min
2–13 98 °C, 20 s 60 °C, 15 s 72 °C, 15 s
14 72 °C, 1 min
34 After the reaction is complete, pool the PCR reactions and purify the PCR 
product by using the QIAquick PCR purification kit according to the 
manufacturer’s directions.
35 Quantify the purified PCR product and run 2 μg of the product on a 2% (wt/vol) 
agarose gel. Successful reactions should yield a ~260–270bp product for the 
knockout library and a ~270–280bp product for the activation library. Gel extract 
using the QIAquick gel extraction kit according to the manufacturer’s directions.
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Pause Point Gel-extracted samples can be stored at −20 °C for several months.
36 Quantify the gel-extracted samples using the Qubit dsDNA HS Assay Kit 
according to the manufacturer’s instructions.
37 Sequence the samples on the Illumina MiSeq or NextSeq according to the 
Illumina user manual with 80 cycles of read 1 (forward) and 8 cycles of index 1. 
We recommend sequencing with 5% PhiX control on the MiSeq or 20% PhiX on 
the NextSeq to improve library diversity and aiming for a coverage of >100 
reads per sgRNA in the library.
38 Analyze sequencing data with count_spacers.py. We provide a python script for 
analyzing the NGS results for the sgRNA representation (Supplementary Data 
3). Install python 2.7 (https://www.python.org/downloads/) and biopython 
(http://biopython.org/DIST/docs/install/Installation.html). Prepare a csv file 
containing the guide spacer sequences with each line corresponding to one 
sequence.
39 To determine the spacer distribution, run python count_spacers.py with the 
following optional parameters:
Flag Description Default
-f Fastq file containing NGS data for analysis NGS.fastq
-o Output csv file with guide spacer sequences in the first column and 
respective read counts in the second column
library_count.csv
-i Input csv file with guide spacer sequences library_sequences.csv
-no-g Indicate absence of a guanine before the guide spacer sequence guanine is present
After running count_spacers.py, spacer read counts will be written to an output 
csv file. Relevant statistics including the number of perfect guide matches, non-
perfect guide matches, sequencing reads without key, the number of reads 
processed, percentage of perfectly matching guides, percentage of undetected 
guides, and skew ratio will be written to statistics.txt. An ideal sgRNA library 
should have more than 70% perfectly matching guides, less than 0.5% 
undetected guides, and a skew ratio of less than 10.
Critical Step The human SAM libraries do not have a guanine before the guide 
spacer sequence, so make sure to run the script with the parameter -no-g when 
analyzing those libraries.
Troubleshooting
Lentivirus production and titer o TIMING 1–2 w
40 Perform an antibiotic kill curve. Prior to lentivirus production and titer, we 
recommend performing a kill curve for the antibiotic used to select the sgRNA 
library and additional necessary components on the relevant cell line for 
screening. To do so, seed cells at 10% confluency in media containing a range of 
antibiotic concentrations typically used for selection.
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41 Refresh media with antibiotic every 3 days. After 4–7 days, choose the lowest 
concentration of antibiotic sufficient to kill all cells.
Critical Step It is important to use the lowest concentration of antibiotic to 
avoid excessively stringent selection that biases selection for cells transduced 
with multiple sgRNAs.
42 HEK 293FT maintenance. Culture cells in D10 medium at 37 °C with 5% CO2 
and maintain according to the manufacturer’s recommendation.
43 To passage, aspirate the medium and rinse the cells by gently adding 5 ml of 
TrypLE to the side of the T225 flask, so as not to dislodge the cells. Remove the 
TrypLE and incubate the flask for 4–5 min at 37 °C until the cells have begun to 
detach. Add 10 ml of warm D10 to the flask and dissociate the cells by pipetting 
them up and down gently, and transfer the cells to a 50-ml Falcon tube.
Critical Step We typically passage cells every 1–2 d at a split ratio of 1:2 or 1:4, 
never allowing cells to reach more than 70% confluency. For lentivirus 
production, we recommend using HEK 293FT cells with a passage number less 
than 10.
44 Preparation of cells for transfection. Seed the well-dissociated cells into T225 
flasks 20–24 h before transfection at a density of 1.8 × 107 cells per flask in a 
total volume of 45 ml D10 medium. Refer to the following table for the number 
of T225 flasks recommended for each plasmid construct:
Plasmid construct Number of T225 flasks
sgRNA library 4
Additional Cas9 nuclease or activator components 2 per component
GFP transfection control 1
Critical Step Do not plate more cells than the recommended density, as doing 
so may reduce transfection efficiency.
45 Lentivirus plasmid transfection. Cells in T225 flasks from Step 44 are optimal 
for transfection at 80–90% confluency. We outline below a transfection method 
using Lipofectamine 2000 and PLUS reagent. Alternatively, we describe a cost-
effective method for lentivirus transfection with Polyethylenimine (PEI) in Box 
5. For each lentiviral target, combine the following lentiviral target mix in a 15-
ml or 50-ml Falcon tube and scale up accordingly:
Component Amount per T225 flask
Opti-MEM 2250 μl
pMD2.G (lentiviral helper plasmid) 15.3 μg
psPAX (lentiviral helper plasmid) 23.4 μg
Lentiviral target plasmid 30.6 μg
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Critical Step Transfecting at the recommended cell density is crucial for 
maximizing transfection efficiency. Lower densities can result in Lipofectamine 
2000 toxicity for cells, while higher densities can reduce transfection efficiency.
46 Prepare the PLUS reagent mix as follows and invert to mix:
Component Amount per T225 flask
Opti-MEM 2250 μl
PLUS reagent   297
47 Add the PLUS reagent mix to the lentiviral target mix, invert, and incubate at 
room temperature for 5 min.
48 Prepare the Lipofectamine reagent mix as follows and invert to mix:
Component Amount per T225 flask
Opti-MEM 4500 μl
Lipofectamine 2000   270
49 Add the lentiviral target and PLUS reagent mix to the Lipofectamine reagent 
mix, invert, and incubate at room temperature for 5 min.
50 Pipette 9 ml of the lentiviral transfection mix from Step 49 into each T225 flask 
from Step 44 and shake gently to mix. Return the T225 flasks to the incubator.
51 After 4 h, replace the medium with 45 ml of pre-warmed D10 medium. The 
constitutive GFP expression plasmid transfection control indicates transfection 
efficiency.
Troubleshooting
52 Harvest and store lentivirus. 2 d after the start of lentiviral transfection, pool the 
lentivirus supernatant from the T225 flasks transfected with the same plasmid 
construct and filter out cellular debris using Millipore’s 0.45 μm Stericup filter 
unit.
Pause Point The filtered lentivirus supernatant can be aliquoted and stored at 
−80 °C. Avoid freeze-thawing lentivirus supernatant.
53 Determine the lentiviral titer through transduction. The CRISPR-Cas9 system 
has been used in a number of mammalian cell lines. Conditions may vary for 
each cell line. Lentiviral titer should be determined using the relevant cell line 
for the screen. Below we detail transduction conditions and calculation of viral 
titer for HEK 293FT cells (option A) and hESC HUES66 cells (option B).
A. Lentiviral transduction and titer for HEK 293FT cells by spinfection
i. HEK 293FT maintenance and passaging. Refer to Steps 42–
43.
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ii. Preparation of cells for spinfection. For each lentivirus, seed 6 
wells of a 12-well plate at a density of 3 × 106 cells in 2 ml 
D10 medium per well with 8 μg ml−1 of polybrene. In each 
well, add 400 μl, 200 μl, 100 μl, 50 μl, 25 μl, or 0 μl of 
lentivirus supernatant from Step 52. Mix each well thoroughly 
by pipetting up and down.
iii. Spinfect the cells by centrifuging the plates at 1000 × g for 2 
h at 33 °C. Return the plates to the incubator after spinfection.
iv. Replating spinfection for calculation of viral titer. 24 h after 
the end of spinfection, remove the medium, gently wash with 
400 μl TrypLE per well, add 100 μl of TrypLE, and incubate 
at 37 °C for 5 min to dissociate the cells. Add 2 ml of D10 
medium per well and resuspend the cells by pipetting up and 
down.
v. Determine the cell concentration using the Cellometer Image 
Cytometer for the 0 μl lentivirus supernatant condition.
vi. For each virus condition, seed 4 wells of a 96-well clear 
bottom black tissue culture plate at a density of 4 × 103 cells 
(from Step 53Aiv) based on the cell count determined in Step 
53Av in 100 μl of D10 medium. Add an additional 100 μl of 
D10 medium with the corresponding selection antibiotic for 
the virus at an appropriate final concentration to 2 wells and 
100 μl of regular D10 medium to the other 2 wells.
vii. 72–96 h after replating, when the no virus conditions contain 
no viable cells and the no antibiotic selection conditions are at 
80–90% confluency, quantify the cell viability for each 
condition using CellTiter Glo according to the manufacturer’s 
protocol.
Critical Step We have found that Cell Titer Glo can be 
diluted 1:4 in PBS to reduce cost while still achieving optimal 
results.
viii. For each virus condition, calculate the multiplicity of 
infection (MOI) as the average luminescence, or viability, of 
the 2 wells in the condition with antibiotic selection divided 
by the average luminescence of the 2 wells in the condition 
without antibiotic selection. A linear relationship between 
lentivirus supernatant volume and MOI is expected at lower 
volumes, with saturation achieved at higher volumes.
B. Lentiviral transduction and titer for hESC HUES66 cells by mixing
i. HUES66 maintenance. We routinely maintain HUES66 cells 
(a hESC cell line) in feeder-free conditions with mTeSR1 
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medium on GelTrex-coated tissue culture plates. To coat a 
100-mm tissue culture dish, dilute cold GelTrex 1:100 in 5 ml 
of cold DMEM, cover the entire surface of the culture dish, 
and place the dish in the incubator for at least 30 min at 
37 °C. Aspirate the GelTrex mix prior to plating. During 
passaging and plating, mTeSR1 medium is supplemented 
further with 10 μM ROCK inhibitor. Refresh the mTeSR1 
medium daily.
ii. Passaging HUES66. Aspirate the medium and rinse the cells 
once by gently adding 10 ml of DPBS to the side of the 100-
mm tissue culture dish, so as not to dislodge the cells. 
Dissociate the cells by adding 2 ml of Accutase and incubate 
at 37 °C for 3–5 min until the cells have detached. Add 10 ml 
of DMEM, resuspend the dissociated cells, and pellet the cells 
at 200 × g for 5 min. Remove the supernatant, resuspend the 
cells in mTeSR1 medium with 10 μM ROCK inhibitor and 
replate the cells onto GelTrex-coated plates. Replace with 
normal mTeSR1 medium 24 h after plating.
Critical Step We typically passage cells every 4–5 d at a split 
ratio of 1:5 or 1:10, never allowing cells to reach more than 
70% confluency.
iii. Preparation of cells for lentiviral transduction. For each 
lentivirus, plate 6 wells of a Geltrex-coated 6-well plate at a 
density of 5 × 105 cells in 2 ml mTeSR1 medium per well. In 
each well, add 400 μl, 200 μl, 100 μl, 50 μl, 25 μl, or 0 μl of 
lentivirus supernatant, fill to a total volume of 3 ml with 
DPBS, and supplement with 10 μM ROCK inhibitor. Plate an 
additional no antibiotic selection control well at the same 
seeding density without virus. Mix each well thoroughly by 
pipetting up and down.
iv. 24 h after lentiviral transduction, replace the medium with 
mTeSR1 containing the relevant antibiotic selection. For the 
no antibiotic selection control well, replace the medium with 
normal mTeSR1 medium. Refresh the mTeSR1 medium with 
and without antibiotic selection every day until the plate is 
ready for the next step.
v. Calculation of viral titer. 72–96 h after starting the antibiotic 
selection, when the no virus condition contains no viable cells 
and the no antibiotic selection control condition is 80–90% 
confluent, rinse the cells with 2 ml of DPBS, add 500 μl of 
Accutase, and incubate at 37 °C for 3–5 min to dissociate the 
cells. Add 2 ml of DMEM and mix well.
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vi. Count and record the number of cells in each well using the 
Cellometer Image Cytometer.
vii. For each virus condition, calculate the MOI as the number of 
cells in the antibiotic selection condition divided by the 
number of cells in the no antibiotic selection control. A linear 
relationship between lentivirus supernatant volume and MOI 
is expected at lower volumes, with saturation achieved at 
higher volumes.
Troubleshooting
Lentiviral transduction and screening o TIMING 3–6 w—CRITICAL: Skip to Step 
56 if screening using a 1-vector format.
54 Generation of a cell line with stably expressed Cas9 components. Prior to 
transducing the sgRNA library, transduce the relevant cell line with the 
additional Cas9 components that are not present in the sgRNA library backbone 
at an MOI < 0.7. If two additional Cas9 components are required, for instance 
dCas9-VP64 and MS2-p65-HSF1, both components can be transduced at the 
same time. Scale up as necessary to generate sufficient cells for maintaining 
sgRNA representation after sgRNA library transduction and selection. We have 
found that generation of a clonal line with Cas9 or SAM components is not 
necessary for successful screening. The cells can therefore be transduced and 
selected as a bulk population at the desired scale. Below we describe lentiviral 
transduction and cell line generation methods for HEK 293FT cells (option A) 
and hESC HUES66 cells (option B).
A. Generation of HEK 293FT cell lines
i. Seed cells in 12-well plates at a density of 3 × 106 cells in 2 
ml D10 medium per well with 8 μg ml−1 of polybrene. Add 
the appropriate volume of lentivirus supernatant from Step 52 
to each well, and make sure to include a no virus control. Mix 
each well thoroughly by pipetting up and down.
ii. Spinfect the cells by spinning the plates at 1000 × g for 2 h at 
33 °C. Return the plates to the incubator after spinfection.
iii. 24 h after the end of spinfection, remove the medium, gently 
wash with 400 μl TrypLE per well, add 100 μl of TrypLE, and 
incubate at 37 °C for 5 min to dissociate the cells. To each 
well, add 2 ml of D10 medium with the appropriate selection 
antibiotic for the lentivirus and resuspend the cells by 
pipetting up and down.
iv. Pool the resuspended cells from the wells with virus and seed 
the cells into T225 flasks at a density of 9 × 106 cells per flask 
in 45 ml of D10 medium with selection antibiotic.
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v. Transfer the resuspended cells from the no virus control into a 
T75 and add 13 ml of D10 medium with selection antibiotic.
vi. Refresh the selection antibiotic every 3 d and passage as 
necessary for 4–7 d and until there are no viable cells in the 
no virus control.
B. Generation of HUES66 cell lines
i. Seed cells in Geltrex-coated 6-well plates at a density of 5 × 
105 cells in of 2 ml mTeSR1 medium per well. Add the 
appropriate volume of lentivirus supernatant from Step 52 to 
each well, and make sure to include a no virus control. Fill up 
the total volume to 3 ml with DPBS, and supplement with 10 
μM ROCK inhibitor. Mix each well thoroughly by pipetting 
up and down.
ii. 24 h after lentiviral transduction, replace the medium with 
mTeSR1 containing the relevant selection antibiotic. Refresh 
the mTeSR1 medium with selection antibiotic every day and 
passage as necessary for 4–7 d and until there are no viable 
cells in the no virus control.
Critical Step The lentiviral transduction method for generating a cell line for 
screening should be consistent with the method for titering the virus to ensure 
that cells are transduced at the appropriate MOI.
55 After selecting for successfully transduced cells, allow the cells to recover from 
selection by culturing in normal medium for 2–7 d before transducing with the 
sgRNA library. If culturing for more than 7 d after selection or after freezing 
cells, re-select the Cas9 component cell line with the appropriate selection 
antibiotic to ensure expression of the Cas9 components and allow the cells to 
recover before sgRNA library transduction.
Pause Point Cells can be frozen according to the manufacturer’s protocol.
56 Transduction of cells with the sgRNA library. Repeat Steps 54–55 for lentiviral 
sgRNA library transduction at the appropriate MOI and selection of transduced 
cell lines. To ensure that most cells receive only one genetic perturbation, 
transduce the sgRNA library at an MOI < 0.3. Scale up the transduction such 
that the sgRNA library has a coverage of >500 cells expressing each sgRNA. For 
example, for a library size of 100,000 unique sgRNAs, transduce 1.67 × 108 
cells at an MOI of 0.3. After the appropriate selection for 4–7 days, the cells are 
ready for screening. For knockout screening, we have found that maximal 
knockout efficiency is achieved 7 days after sgRNA transduction and therefore 
recommend selecting for 7 days before starting the screen selection. In contrast, 
maximal SAM activation is achieved as early as 4 days after sgRNA 
transduction. If selection is complete based on the no virus control, gain-of-
function screening can be started 5 days after transduction. We generally 
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recommend to perform 4 independent screening bioreps (i.e. 4 separate sgRNA 
library infections followed by separate screening selection). Multiple screening 
bioreps are critical for determining screening hits with a high rate of validation. 
Since the parameters of each screen depends on the screening phenotype of 
interest, we provide guidelines and technical considerations for the screening 
selection process (Box 2–4).
Critical Step It is important to aim for a coverage of >500 cells per sgRNA to 
guarantee that each perturbation will be sufficiently represented in the final 
screening readout. Increase the coverage as necessary if the screening selection 
pressure is not very strong or if performing a negative selection screen. 
Transducing the sgRNA library at an MOI < 0.3 ensures that most cells receive 
at most one genetic perturbation. Transducing at higher MOI’s may confound 
screening results.
Harvest genomic DNA for screening analysis o TIMING 5–7 d
57 Harvest genomic DNA. At the end of the screen, harvest genomic DNA (gDNA) 
from a sufficient number of cells to maintain a coverage of >500. For a library 
size of 100,000 unique sgRNAs, harvest gDNA from at least 5 × 107 cells for 
downstream sgRNA analysis using the Zymo Research Quick-gDNA MidiPrep 
according to the manufacturer’s protocol. Elution should be performed twice 
with 150–200 μl each for maximum recovery of gDNA.
Critical Step Make sure to tighten the connection between the reservoir and the 
column and centrifuge at a sufficient speed and time to remove any residual 
buffer. Addition of a final dry spin is recommended to remove residual wash 
buffer.
Pause Point Frozen cell pellets or isolated gDNA can be stored at −20 °C for 
several months.
58 Preparation of the gDNA for NGS analysis. Refer to Steps 32–33 for how to 
amplify the sgRNA for NGS. Scale up the number of reactions such that all of 
the gDNA harvested from the screen is amplified. Each 50 μl reaction can hold 
up to 2.5 μg of gDNA. Barcoded NGS-Lib-Rev primers enable sequencing of 
different screening conditions and bioreps (i.e. experimental condition biorep 1 
and control condition biorep 1) in a pooled sequencing run.
Troubleshooting
59 Purification of amplified screening NGS library. For large-scale PCR 
purification, we recommend using the Zymo-Spin V with Reservoir. Add 5 
volumes of DNA Binding Buffer to the PCR reaction, mix well, and transfer to 
Zymo-Spin V with Reservoir in a 50 ml Falcon tube. Each Zymo-Spin V 
column can hold up to 12 ml.
Critical Step Make sure to tighten the connection between the reservoir and the 
Zymo-Spin V column.
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60 Centrifuge at 500 × g for 5 min at room temperature. Discard the flow-through.
61 Add 2 ml of DNA Wash Buffer and centrifuge at 500 × g for 5 min at room 
temperature. Discard the flow-through and repeat for an additional wash.
62 Remove the reservoir from the Zymo-Spin V column and transfer the column to 
a 2 ml collection tube. In a microcentrifuge, spin at the maximum speed 
(>12,000 × g) for 1 min at room temperature to remove residual wash buffer.
63 Transfer the Zymo-Spin V column to a 1.5 ml microcentrifuge tube. Add 150 μl 
of elution buffer, wait for 1 min, and spin at the maximum speed (>12,000 × g) 
for 1.5 min at room temperature to elute the purified PCR reaction.
64 Pool the purified PCR reactions and quantify. Refer to Steps 37–39 for NGS 
analysis of the sgRNA distribution. For screening NGS analysis, we recommend 
aiming for a coverage of >500 reads per sgRNA in the library.
65 Analysis of screening results with RNAi gene enrichment ranking (RIGER). 
Prior to RIGER analysis, determine the sgRNA fold change due to screening 
selection. For each biorep of screening experimental or control condition, add a 
pseudocount of 1 to the NGS read count of each sgRNA and normalize by the 
total number of NGS read counts for that condition. To obtain the sgRNA fold 
change, divide the experimental normalized sgRNA count by the control and 
take the base 2 logarithm.
66 Prepare a RIGER input csv file with the column headers WELL_ID, GENE_ID, 
and biorep 1, biorep 2, etc from left to right. WELL_ID is a list of sgRNA 
identification numbers, GENE_ID the genes that the sgRNAs target, and biorep 
columns the sgRNA fold change. Each row contains a different sgRNA in the 
library.
67 RIGER is launched through GENE-E from the Broad Institute (http://
www.broadinstitute.org/cancer/software/GENE-E/download.html). Start GENE-
E and import the input csv file by navigating to File > Import > Ranked Lists. 
Click the table cell containing the first data row and column as instructed. 
Launch RIGER by going to Tools > RIGER. Adjust the RIGER settings to the 
following recommended values:
Number of permutations: 1,000,000
Method to convert hairpins to genes: Kolmogorov-Smirnov
Gene rank order: Positive to negative for positive selection screens; negative to positive for negative 
selection screens
Select adjust gene scores to accommodate variation in hairpin set size
Select hairpins are pre-scored
Hairpin Id: WELL_ID
Convert hairpins to: GENE_ID
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68 Once the RIGER analysis has completed, export the gene rank dataset. 
Determine the top candidates genes based on either the overlap or the average 
ranking between the screening bioreps.
Validation of candidate genes for screening phenotype o TIMING 4–5 w
69 Cloning validation sgRNAs into the plasmid backbone of the sgRNA library. 
Design top and bottom strand primers for cloning the top 3 sgRNAs for each 
candidate gene individually into the plasmid backbone of the sgRNA library 
used for screening according to Table 5 as we have previously described72. 
Primers for cloning 2 non-targeting sgRNAs (NT1 and NT2) for control are also 
provided in Table 5.
70 Resuspend the top and bottom strand primers to a final concentration of 100 μM. 
Prepare the following mixture for phosphorylating and annealing the top and 
bottom strand primers for each validation sgRNA:
Component Amount (μl) Final concentration
sgRNA-top, 100 μM 1 10 μM
sgRNA-bottom, 100 μM 1 10 μM
T4 ligation buffer, 10× 1 1×
T4 PNK 0.5
UltraPure water 6.5
Total 10
71 Phosphorylate and anneal the primers in a thermocycler using the following 
conditions: 37 °C for 30 min; 95 °C for 5 min; ramp down to 25 °C at 5 °C 
min−1.
72 After the annealing reaction is complete, dilute the phosphorylated and annealed 
oligos 1:10 by adding 90 μl of UltraPure water.
Pause Point Annealed oligos can be stored at −20 °C for at least 1 week.
73 Clone the annealed sgRNA inserts into the sgRNA library backbone by setting 
up a Golden Gate assembly reaction for each sgRNA. We have found that when 
cloning many sgRNAs, Golden Gate assembly is efficient and offers a high 
cloning success rate. Mix the following for each sgRNA:
Component Amount (μl) Final concentration
Rapid Ligase Buffer, 2× 12.5 1×
FastDigest Esp3I (BsmBI) 1
DTT 0.25 1 mM
BSA, 20 mg ml−1 0.125 0.1 mg ml−1
T7 ligase 0.125
Diluted oligo duplex from Step 72 1 0.04 μM
sgRNA library backbone 1 1 ng μl−1
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UltraPure water 9
Total 25
Critical Step We recommend using FastDigest Esp3I (Fermentas) as we have 
had reports of Esp3I from other vendors not working as efficiently in the Golden 
Gate assembly reaction setup described. It is not necessary to perform a negative 
control (no insert) Golden Gate assembly reaction as it will always contain 
colonies and therefore is not a good indicator of cloning success.
74 Perform a Golden Assembly reaction using the following cycling conditions:
Cycle number Condition
1–15 37 °C for 5 min, 20 °C for 5 min
Pause Point Completed Golden Gate assembly reactions can be stored at 
−20 °C for at least 1 week.
75 Transformation and midiprep. Transform the Golden Gate assembly reaction 
into a competent E. coli strain, according to the protocol supplied with the cells. 
We recommend the Stbl3 strain for quick transformation. Thaw the chemically 
competent Stbl3 cells on ice, add 2 μl of the product from Step 74 into ice-cold 
Stbl3 cells, and incubate the mixture on ice for 5 min. Heat-shock the mixture at 
42 °C for 30 s and return to ice immediately for 2 min. Add 100 μl of SOC 
medium and plate it onto a standard LB agar plate (100 mm Petri dish, 
ampicillin). Incubate it overnight at 37 °C.
76 The next day, inspect the plates for colony growth. Typically, there should be 
tens to hundreds of colonies on each plate.
Troubleshooting
77 From each plate, pick 1 or 2 colonies for midiprep to check for the correct 
insertion of sgRNA and for downstream lentivirus production. To prepare a 
starter culture for midiprep, use a sterile pipette tip to inoculate a single colony 
into a 3-ml culture of LB medium with 100 μg ml−1 ampicillin. Incubate the 
starter culture and shake it at 37 °C for 4–6 h at >250 rpm.
78 Expand each starter culture by transferring the starter culture to 2 separate 25-ml 
cultures of LB medium with 100 μg ml−1 ampicillin in a 50-ml Falcon tube. 
Remove the cap and seal the top of the tube with AirPore Tape Sheets. Incubate 
the culture and shake it at 37 °C overnight at >250 rpm.
79 12–16 h after seeding the starter culture, isolate the plasmids using an 
endotoxin-free midiprep kit such as the Macherey-Nagel NucleoBond Xtra Midi 
EF kit according to the manufacturer’s protocol.
Critical Step Using an endotoxin-free plasmid purification kit is important for 
avoiding endotoxicity in virus preparation and mammalian cell culture. In our 
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experience, plasmids prepared with endotoxin-free midiprep have higher purity 
and produce higher lentiviral titers.
Pause Point Midiprepped validation sgRNA constructs can be stored at −20 °C 
for at least 1 year.
80 Sequence validation of sgRNA cloning. Verify the correct insertion of the 
validation sgRNAs by sequencing from the U6 promoter using the U6-fwd 
primer. Compare the sequencing results to the sgRNA library plasmid sequence 
to check that the 20-nt sgRNA target sequence is properly inserted between the 
U6 promoter and the remainder of the sgRNA scaffold.
Troubleshooting
81 Generation of validation cell lines. Prepare lentivirus for validation by scaling 
down the lentivirus production in Steps 44–51 to T25 flasks or 2 wells of a 6-
well plate. Filter the lentivirus supernatant using 5-ml syringes and 0.45 μm 
syringe filters.
82 Titer the lentivirus according to Step 53. If preparing multiple validation sgRNA 
lentivirus in the same plasmid backbone at the same time, titer lentivirus from 2–
3 different sgRNAs and extend the average titer to the rest of the lentivirus.
83 Similar to during screening, transduce either naive cells or Cas9 component-
expressing cells with validation sgRNA lentivirus at an MOI < 0.5 according to 
Steps 54–55. For knockout validation, select for 7 d to allow for sufficient time 
for indel saturation.
84 Validation of candidate genes for screening phenotype. Once the antibiotic 
selection for validation cell lines is complete, verify the screening phenotype by 
applying the screening selection on the validation cell lines and assessing cell 
proliferation, death, or fluorescence for positive, negative, and marker gene 
selection screens respectively. In addition, determine the indel rate for knockout 
screens (Steps 85–99) or fold activation for activation screens (Steps 100–110).
85 Indel rate analysis for validating a knockout screen. We describe a two-step PCR 
for NGS in which the first step uses custom primers to amplify the genomic 
region of interest and the second step uses universal, barcoded primers for 
multiplexed sequencing of up to 96 different samples in the same NGS run. For 
each validation sgRNA, design custom round 1 NGS primers (NGS-indel-R1) 
that amplify the 100–300bp region centered around the sgRNA cut site 
according to Table 4. It is important to design primers situated at least 50 bp 
from the target cleavage site to allow for the detection of longer indels. Aim for 
an annealing temperature of 60 °C and check for potential off-target sites using 
Primer-BLAST. If necessary, include a 1–10bp staggered region to increase the 
diversity of the library.
86 Harvest gDNA from validation cell lines. Seed the validation cells at a density of 
60% confluency with 3 bioreps in a 96-well clear bottom black tissue culture 
plate.
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87 1 d after seeding, when the cells have reached confluency, aspirate the media 
and add 50 μl of QuickExtract DNA Extraction Solution. Incubate at room 
temperature for 2–3 min.
88 Scrape the cells with a pipette tip, mix thoroughly by pipetting up and down, and 
transfer the mixture to a 96-well PCR plate.
89 Extract the genomic DNA by running the following cycling conditions:
Cycle number Condition
1 65 °C, 15 min
2 68 °C, 15 min
3 98 °C, 10 min
Pause Point Extracted genomic DNA can be stored at −20 °C for up to several 
months.
90 First round PCR for indel analysis by NGS. Amplify the respective target 
regions for each validation and control cell line by using custom NGS-indel-R1 
primers (Table 4) in the following reaction:
Component Amount (μl) Final concentration
KAPA HiFi HotStart ReadyMix, 2× 10 1×
First round PCR from Step 91 1
NGS-indel-R2-Fwd 1 0.5 μM
NGS-indel-R2-Rev 1 0.5 μM
UltraPure water 7
Total 20
Critical Step To minimize error in amplifying sgRNAs, it is important to use a 
high-fidelity polymerase. Other high-fidelity polymerases, such as PfuUltra II 
(Agilent) or NEBNext (New England BioLabs), may be used as a substitute.
91 Perform a PCR with the following cycling conditions:
Cycle number Denature Anneal Extend
1 98 °C, 3 min
2–23 98 °C, 10 s 63 °C, 10 s 72 °C, 25 s
14 72 °C, 2 min
92 Second round PCR for indel analysis by NGS. Barcode the first round PCR for 
NGS by amplifying the product with different NGS-indel-R2 primers (Table 4) 
in the following reaction:
Component Amount (μl) Final concentration
KAPA HiFi HotStart ReadyMix, 2× 10 1×
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QuickExtract from Step 89 1
NGS-indel-R1-Fwd 1 0.5 μM
NGS-indel-R1-Rev 1 0.5 μM
UltraPure water 7
Total 20
93 Perform a PCR using the same cycling conditions as described in Step 91.
94 After the reaction is complete, run 5 μl of each amplified target on a gel to verify 
successful amplification of a single product at the appropriate size. Cast a 2% 
(wt/vol) agarose gel cast in TBE buffer with SYBR Safe dye and run the gel at 
15 V cm−1 for 30 min.
Troubleshooting
95 Pool the PCR products and purify the pooled product using the QIAquick PCR 
purification kit, according to the manufacturer’s instructions.
Critical Step Due to variable PCR efficiencies and product lengths, pooling 
without normalization may result in variation in NGS representation. When 
pooling without normalization, aim for 20,000–40,000 reads per sgRNA during 
sequencing. Alternatively, if sequencing reads are limited, consider purifying 
each barcoded PCR product separately, quantifying by NanoDrop, and 
normalizing the PCR products to the same concentration prior to pooling.
96 Run the pooled PCR product on a 2% (wt/vol) agarose gel as described in Step 
94 and gel extract the appropriately sized bands using the QIAquick gel 
extraction kit according to the manufacturer’s directions.
Pause Point Gel-extracted product can be stored at −20 °C for several months.
97 Sequence gel-extracted samples on the Illumina MiSeq according to the Illumina 
user manual with 260 cycles of read 1, 8 cycles of index 1, and 8 cycles of index 
2. We recommend aiming for >10,000 reads per sgRNA.
98 Indel analysis of validation sgRNAs with calculate_indel.py. We provide a 
python script for analyzing the NGS results for indel rates (Supplementary Data 
4). Install python 2.7 (https://www.python.org/downloads/), biopython (http://
biopython.org/DIST/docs/install/Installation.html), and SciPy (https://
www.scipy.org/install.html). Construct a sample sheet with each line 
corresponding to a separate sample. Each line should contain sample name, fasta 
or fastq file name, guide sequence, PCR target amplicon, and experimental or 
control in columns from left to right. The last column is only required when 
performing the maximum likelihood estimate (MLE) correction. When MLE is 
performed, control samples which reflect the background indel rate should be 
labeled “Control” and experimental samples should be labeled “Experimental”. 
Refer to the following table for an example of a sample sheet:
example1 example1.fastq GCCCGATCGCTATATCCACG TGTATATACCTCGCGCCTAACTGCCAGCTGACCACGCCGTACAGGTTCTGTTGTCTACTGATGCATTACATCTCCTTAGGGTACTTCCGCTGAGATCATTGCCCGATCGCTATATCCACGCGTTTGGCTCGTTCAACCAGTCCAACCGACTCGTTGGTCTGGTAATGTGCCCAAGTTAAGGTGAGTATGGACATGGCGGG Experimental
example2 example2.fastq CGAGATAAGTCAGCAGGGGC CTCTTCTGCTCAAGCGAGTTCCCAGAGGTCCTTGCCGAGGGGGTTATATCGATCCACGAAACATAGTATGTAATACGAAAGTCATCGGCGCCTATGCCCTCGAGATAAGTCAGCAGGGGCTTTTCGTACATTTTCCAAGATTCGGGATTGACGTTGCATCGCAAGCTAATTGGTTACCATTAGACCCCAGTCCTCAGCCC Experimental
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example3 example3.fastq CACCCACACCAACCGCAGAA CTGGGTTTAACCGAGCTAGTCCTGAAGATCTTGAGTAACTGCACATGTAAATAATCCGAGGCGTTTTCGGCGCCTAGCATGGCGTGCAAGCTCTCCGCAGCACCCACACCAACCGCAGAAGACAGCCCCTGGGACGTGTAATTTAGCCATGTTGGTCGCTTTCGGGAGCAACAGTGGTGTGGCCGTAGCGGACACCACCA Control
99 If processing all files with a single command, run python calculate_indel.py with 
the following optional parameters:
Flag Description Default
-f Indicates input file is fasta format Fastq file format
-a Uses alternative hashing algorithm for calculation74 Ratcliff-Obershelp based algorithm73
-o Output file with calculated indel rates and statistics calc_indel_out.csv
-i Input file with sample name, fasta or fastq file name, 
guide sequence, PCR target amplicon, and 
experimental or control in columns from left to right
sample_sheet.csv
-v or -q Increase or decrease reporting as script runs Standard reporting
-no-m Does not perform MLE correction MLE correction is performed
For processing individual samples, such as in the case of parallelization, run 
python calculate_indel.py –sample <sample name> to produce a file <sample 
name>_out.csv. Combine individual sample files by calling python 
calculate_indel.py --combine. After running calculate_indel.py, calculated indels 
will be in the output file, which also contains counts of reads that matched 
perfectly, failed to align, or were rejected due to quality, or had miscalled bases/
replacements. There will also be three columns corresponding to the MLE 
corrected indel rate, as well as the upper and lower bounds for the 95% 
confidence interval of indels.
100 Determine the fold activation for validating an activation screen. Prepare cells by 
seeding the validation cells at a density of 60% confluency with 4 bioreps for 
each validation cell line in a 96-well poly-d-lysine coated tissue culture plate.
101 Reverse transcription to cDNA. When the cells are confluent approximately 1 d 
after seeding, prepare the following reagents for each well: Complete RNA lysis 
buffer:
Component Amount (μl) Final concentration
RNA lysis buffer 100
Proteinase K, 300 U ml−1 1 3 U ml−1
DNAse I, 50 KU ml−1 0.6 300 U ml−1
Total 101.6
Reverse Transcription Mix:
Component Amount (μl) Final concentration
Reaction Buffer, 5× 5 1×
dNTP Mix, 10 mM 1.25 0.5 mM
Random Hexamer Primer, 100 μM 1.09 4.4 μM
Oligo dT, 100 μM 0.88 3.5 μM
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RiboLock RNAse Inhibitor, 40 U μl−1 0.125 0.2 U μl−1
RevertAid Reverse Transcriptase, 200 U μl−1 1.25 10 U μl−1
UltraPure water 10.41
Total 20
Except for Oligo dT, all components can be found in the Thermo RevertAid RT 
Reverse Transcription kit.
Critical Step Make sure all reagents are RNAse free and take proper 
precautions when working with RNA.
102 Aliquot 20 μl of the Reverse Transcription Mix into each well of a 96-well PCR 
plate. Thaw the RNA lysis stop solution, prepare cold DPBS, and keep all 
reagents except for the complete RNA lysis buffer on ice until needed.
103 Aspirate the media from each well of the 96-well poly-d-lysine tissue culture 
plate from Step 100, wash with 100 μl of cold DPBS, and add 100 μl of room 
temperature complete RNA lysis buffer from Step 101. Incubate at room 
temperature while mixing thoroughly for 6–12 min to lyse the cells.
Critical Step It is important to limit the lysis time to less than 12 min to prevent 
RNA degradation.
104 Transfer 30 μl of the cell lysate to a new 96-well PCR plate. Add 3 μl of RNA 
lysis stop solution to terminate lysis and mix thoroughly.
Pause Point The cell lysate with RNA lysis stop solution can be stored at 
−20 °C for additional reverse transcription reactions.
105 Then, add 5 μl of the cell lysate with RNA lysis stop solution to the Reverse 
Transcription Mix from Step 101 for a total volume of 25 μl and mix thoroughly.
106 Reverse transcribe the harvested RNA to cDNA with the following cycling 
conditions:
Cycle number Condition
1 25 °C, 10 min
2 37 °C, 60 min
3 95 °C, 5 min
Pause Point The cDNA can be stably stored at −20 °C for 1 year.
107 Perform a TaqMan qPCR for fold activation analysis. Thermo Fisher Scientific 
provides design ready TaqMan Gene Expression Assays for candidate genes as 
well as for endogenous control genes such as GAPDH or ACTB. Make sure that 
the experimental and control gene expression assays have different probe dyes 
(i.e. VIC and FAM dyes) that allow for running in the same reaction. Prepare the 
following qPCR master mix per reverse transcription reaction. We recommend 
pre-mixing the TaqMan Fast Advanced Mastermix and gene expression assays 
for all samples with the same target gene first.
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Component Amount (μl) Final concentration
TaqMan Fast Advanced Master Mix, 2× 12 1×
TaqMan Gene Expression Assays for candidate gene, 20× 1.2 1×
TaqMan Gene Expression Assays for control gene, 20× 1.2 1×
cDNA 9.6
Total 24
108 Aliquot 4 × 5 μl of the qPCR master mix into a 384-well optical plate for 
technical replicates.
Cycle number Hold Denature Anneal/Extend
1 50 °C, 2 min
2 95 °C, 20 s
3–42 95 °C, 3 s 60 °C, 30 s
109 Perform a qPCR with the following cycling conditions:
110 Once the qPCR is complete, calculate the candidate gene expression fold change 
relative to control using the ddCt method according to the instrument 
manufacturer’s protocol.
111 Additional steps for combining candidate genes from knockout and activation 
screens using dead sgRNAs (dRNAs). dRNAs are sgRNAs with 14- or 15-nt 
spacer sequences, which are truncated versions of the standard sgRNAs with 20-
nucleotide spacer sequences, that are still capable of binding DNA75,76. dRNAs 
are considered catalytically ‘dead’ because they can guide wild-type Cas9 
without inducing double-stranded breaks. Adding MS2 binding loops to the 
dRNA backbone allows for wild-type Cas9 to activate transcription without 
cleavage. To achieve simultaneous knockout and activation, repeat Steps 44–55 
to generate a cell line that stably expresses wild-type Cas9 and MS2-p65-HSF1.
112 Transduce the Cas9- and MS2-p65-HSF1-expressing cell line with a standard 
sgRNA for knocking out a candidate gene and a 14-nt dRNA with MS2 binding 
loops for activating a second candidate gene according to Steps 69–83.
113 Verify the screening phenotype, indel percentage, and fold activation according 
to Steps 84–110.
Troubleshooting—Troubleshooting advice can be found in Table 6. To clarify potential 
points of confusion when performing genome-scale screens using CRISPR-Cas9, we have 
compiled a list of most-frequently asked questions from our web-based CRISPR forum 
(discuss.genome-engineering.org) (Box 6). (Fig. 4)
Timing—Steps 1–17, designing and cloning a targeted screen: 3–5 w, 1 w hands-on
Steps 18–31, amplification of pooled sgRNA library: 2 d
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Steps 32–39, next-generation sequencing of the amplified sgRNA library: 3–5 d
Steps 40–53, lentivirus production and titer: 1–2 w
Steps 54–56, lentiviral transduction and selection: 3–6 w
Steps 57–68, harvest genomic DNA for screening analysis: 5–7 d
Steps 69–110, validation of candidate genes: 4–5 w
ANTICIPATED RESULTS
As a reference for screening results, we provide data from genome-scale knockout and 
transcriptional activation screens for genes that confer BRAF inhibitor vemurafenib (PLX) 
resistance in a BRAFV600E (A375) cell line30,37. After applying vemurafenib selection, the 
sgRNA library distribution, which is measured by NGS, in the experimental condition is 
more skewed than the baseline and vehicle control conditions, with some sgRNAs enriched 
and others depleted (Fig. 4a,b). SgRNAs targeting genes involved in vemurafenib resistance 
are enriched because they provide a proliferation advantage upon vemurafenib treatment. 
RIGER analysis of enriched sgRNAs in the vemurafenib condition relative to the control 
identified several candidate genes responsible for resistance. Each candidate gene has 
multiple significantly enriched sgRNAs (Fig. 4c, d) and P values that are significantly lower 
than the rest of the genes (Fig. 4e, f).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Box 1
Different types of selection applicable for CRISPR screens
Before setting up a screen, it is important to determine the type of screening selection 
based on the phenotype of interest and available selection pressures for the screen, as 
illustrated below:
Positive selection screens rely on enrichment of sgRNAs for genetic perturbations that 
produce the screening phenotype as a result of cell proliferation. These typically have the 
highest signal-to-noise ratio compared to the other types of screens because the number 
of phenotypically relevant sgRNAs increases relative to the rest of the sgRNAs. On the 
other hand, negative selection screens involve depletion of sgRNAs that correspond to the 
phenotype due to cell death. However, for a large number of screens the phenotype of 
interest will not result in cell proliferation or cell death and thus the phenotypically 
relevant sgRNAs are not enriched or depleted. For these phenotypes, the screen may be 
read out by capturing sgRNAs that produce changes in marker gene protein expression 
using either endogenous-tagged fluorescent proteins or highly specific antibodies 
followed by FACS.
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Box 2
Considerations for setting screening parameters
Optimal screening parameters should maximize the difference in sgRNA distribution 
between the experimental and control conditions. Selection conditions such as drug 
dosage or FACS bin cutoff should be predetermined, if possible, using positive and 
negative controls from the literature and set to the level at which the greatest difference is 
observed. As for determining the duration of the screen, collection of time points 
throughout the screen helps identify the best time point for harvesting and analyzing the 
screen. These time points are also informative for assessing whether it is necessary to 
increase the duration to enhance the difference between experimental and control 
conditions.
Throughout the screen, it is imperative to maintain sufficient coverage to avoid losing 
sgRNA representation or bias the screening results. Try to maintain sufficient coverage at 
>500 cells per sgRNA in the library during library transduction, screening selection, and 
screening harvest. In addition, we recommend 2–4 infection replicates per screen to 
account for stochastic noise. Increase the coverage and number of infection replicates if 
the screening selection is noisy. Finally, consistency of screening conditions such as 
sgRNA representation and passaging reduces the variability between infection replicates.
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Box 3
Additional considerations for ex vivo and in vivo pooled screening
Ex vivo screening involves removing a primary cell type of interest from a living animal, 
culturing them in vitro and then performing the screen. For example, Parnas et al. 
demonstrated this strategy by deriving immune dendritic cells from Cas9 mice, 
transducing them with a CRISPR knockout library, triggering an immune response with 
lipopolysaccharide (LPS), and then FACS sorting different populations of cells based on 
immune response (e.g. TNF expression)44. This ex vivo screen identified many known as 
well as novel regulators of LPS response. When performing an ex vivo screen, it is 
necessary to be able to obtain enough cells to maintain library representation, deliver 
appropriate reagents to the cells, and culture the cells for long enough to perform the 
screen. In cases where these conditions cannot be met, adapt the screening strategy by, 
for instance, reducing the library size to capture a subset of genes.
In vivo screening is performed with either a) transduction of cells in vitro followed by in 
vivo cell transplantation, or b) direct transduction of tissues in vivo. The first strategy was 
demonstrated by Chen et al., whereby a cancer cell line was transduced with a CRISPR 
knockout library and injected subcutaneously in immunocompromised mice42. NGS 
analysis of harvested tumors identified known and novel tumor suppressors associated 
with tumor growth and metastasis. The main challenge of this approach is engrafting 
cells in vivo. Special care must be taken to ensure that the library is not only maintained 
upon infection of cells in vitro but also after engraftment of cells in vivo. While it is not 
required to maintain library representation on a per animal basis, a sufficient number of 
animals should be used such that library representation is maintained for each 
experimental cohort. Because the engraftment efficiency and time of engraftment can 
change for each application it is necessary to sequence the library at several time points 
after injection of cells in vivo. The optimal time point is one where engraftment is 
complete and selection (i.e. proliferation, death, or migration) has not yet occurred. 
Identifying this time point is critical as it is used as a reference to identify enriched and/or 
depleted perturbations.
For the second method of in vivo screening, special considerations will vary widely 
depending on the specific animal model, tissue, cell type, developmental time point, or 
biological question. Thus, each screen should be uniquely designed. In addition to the 
screening considerations outlined previously, the additional challenge for this strategy is 
the delivery of reagents in a complex environment while maintaining library 
representation and also infecting cells at a low MOI. Beyond specific circumstances, it 
may not be feasible to achieve appropriate cell numbers suitable for a genome-scale 
library. In these cases it is recommended to design smaller, targeted libraries with a 
specific hypothesis in mind. The complexity of the in vivo environment makes it difficult 
to meet the critical requirements for performing an informative screen. In assessing 
whether a direct in vivo screening strategy is feasible for any particular application, 
consider these guiding questions: 1) Is there a delivery strategy for infecting the target 
cells at low MOI? 2) Can enough of the target population be infected and purified to 
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maintain library representation? 3) Can a reference population be identified before the 
guide RNA abundance changes?
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Box 4
Designing and analyzing a saturated mutagenesis screen
Although most pooled CRISPR screens to date have focused on knockout or activation of 
protein-coding genes, CRISPR screens can also be used to identify functional elements in 
noncoding regions of the genome such as enhancers or repressors. These functional 
elements are often inferred using biochemical hallmarks associated with function (e.g. 
chromatin accessibility, transcription factor binding sites, or post-translational histone 
modifications). In contrast, CRISPR screens enable direct testing of how mutagenesis at a 
specific noncoding site impacts phenotype.
Several strategies can be used to design libraries to target noncoding regions. For 
understanding regulation of a particular gene, tiling mutagenesis libraries were designed 
to include many or all possible target sites within a noncoding region near a gene53,56,57. 
This allows unbiased identification of all regulatory elements in regions near a gene that 
has already been established to be important for the screening phenotype, as illustrated 
below:
Another approach is to design the library to target all instances across the genome of a 
specific biochemical hallmark, such as all binding sites of a transcription factor like 
p5354. With this kind of library, it is possible to identify specific binding sites or 
regulatory elements associated with a phenotype of interest.
As with screening the coding genome, a key factor in assessing the performance of the 
screen is to find multiple sgRNAs targeting the same element that are enriched or 
depleted together. In coding regions, this is straightforward, as the library is designed to 
have multiple sgRNAs that target the same gene. In noncoding regions, the same 
principle of consistent enrichment or depletion can be applied to multiple sgRNAs that 
target neighboring regions, as the indels are of variable length. Once a functional element 
is validated using multiple sgRNAs with adjacent target sites, expression of nearby genes 
and potential mechanisms such as alterations in transcription factor binding at the site can 
be used to gain further insight into biological mechanisms.
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Box 5
Lentivirus production with Polyethylenimine
1. Prepare polyethylenimine (PEI) transfection reagent. Dissolve 50 mg PEI 
Max in 45 ml UltraPure Water. Adjust pH to 7.1 by adding 10 M NaOH 
dropwise until the pH approaches 6 and then by adding 1 M NaOH dropwise 
until final pH reaches 7.1. Adjust final volume to 50 ml with UltraPure Water. 
Sterilize using Millipore’s 0.45 μm Steriflip filter. Prepare 50 × 1 ml aliquots 
and store at −20 °C until use. PEI is stable for up to one year and can undergo 
5 freeze-thaw cycles without a drop in transfection efficiency.
2. Lentivirus plasmid transfection. Prepare HEK293FT cells for lentivirus 
transfection as described in Steps 42–44.
3. For each lentiviral target, combine the following lentiviral target mix in a 50-
ml Falcon tube and scale up accordingly:
Component Amount per T225 flask Final Concentration
DMEM (serum free) 651 μl
pMD2.G (lentiviral helper plasmid) 3.4 μg 5.2 μg ml−1
psPAX2 (lentiviral helper plasmid) 6.8 μg 10.4 μg ml−1
Lentiviral target plasmid μg 20.9 μg ml−1
4. Add 195 μl PEI transfection reagent, vortex, and incubate at room 
temperature for 10 min.
5. Add 25 ml D10 media to the transfection reagent mixture.
6. Aspirate old media from cells, gently add new media containing the 
transfection reagent mixture and shake gently to mix. Return the T225 flask to 
the incubator.
7. 2 d after transfection, harvest and store lentivirus as described in Step 52.
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Box 6
Frequently asked screening questions from the CRISPR Forum
The following questions are selected from the CRISPR Discussion Forum 
(discuss.genome-engineering.org).
Q1: Can I use liquid culture amplification of the library rather than solid plates?
We recommend using plates because liquid culture can generate more bias in the plasmid 
library. Beta-lactamase, the enzyme responsible for ampicillin resistance, is secreted and 
eventually in liquid culture the selective pressure on the plasmid is decreased causing 
bias. Additionally, it is more difficult for certain clones to predominate on solid plates 
because they are spatially limited in growth and each clone is spatially separated to 
prevent potential intercolony competition. However, it is important to note that some 
studies have had success with liquid culture amplification45.
Q2: Is there a difference between using HEK293FT vs HEK293T cells for lentivirus 
production?
Yes, HEK293FT cells are generally more ideal for lentivirus production. HEK293T cells 
are a cell line stably expressing the SV40 large T antigen, which helps to boost protein 
production off expression constructs containing the SV40 enhancer element. HEK293FT 
cells are a fast-growing, highly transfectable clonal derivation of HEK293T cells that 
yield higher lentivirus titer than the HEK293T line.
Q3: For activation, how do I design guides relative to the TSS of the transcript? 
Additionally, can I expect these guides to work with transient transfection of dCas9-
VP64 and MS2-VP65-HSF1 plasmids?
The TSS is the first base of the transcript, i.e. beginning of the 5′ UTR. The UCSC table 
browser is a good resource for TSS annotations. We have observed the most robust 
transcriptional upregulation when sgRNAs are designed to target the 200bp region 
upstream of the TSS. We have created a web tool using these parameters to simplify 
activation sgRNA design for human and mouse genes (http://sam.genome-
engineering.org/database/). SAM is highly robust and should yield significant activation 
levels even in the case of transient transfection36.
Q4: What are important considerations for NGS PCR amplification?
When designing primers, it is important to include stagger between the primer binding 
site and the Illumina adapter sequence such that the sequencing regions of different 
amplicons are offset, improving the sequence diversity and quality. For genomic DNA 
amplification, it can be helpful to optimize the DNA input for the sequencing readout 
PCR step. Generally, it is recommended for any given instance of the screen to titrate the 
DNA input and use the highest possible input without a decrease in the target band 
intensity. It is critical to minimize amplification bias. The optimal cycle number should 
always be determined by doing a series of different cycle numbers (e.g. 5, 10, and 15) 
and identifying the lowest cycle number that generates a visible band by gel 
electrophoresis. Avoid conditions that yield additional bands at higher cycle numbers.
Joung et al. Page 54
Nat Protoc. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Q5: My screening design requires too many cells. Can I reduce the coverage?
We recommend screening at a coverage of >500 cells per sgRNA. Because there is 
always variability in the copy number of each sgRNA in a given library, it is important to 
have high coverage to overcome any bias. If it is impossible to screen at this coverage 
(e.g. insufficient primary cells or cells are difficult to transduce), consider screening with 
a smaller, targeted library.
Q6: How do you measure the quality of a cloned plasmid library?
While there are many methods for determining the quality of a library, we typically use 
the following measures for a sequencing depth of >100 reads per sgRNA:
1. Overall representation: <0.5% of sgRNAs have dropped out with no reads.
2. Library uniformity: <10-fold difference between the 90th percentile and the 
10th percentile.
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Figure 1. Approaches to genetic perturbation: shRNA knockdown, Cas9 knockout, and Cas9 
transcriptional activation
Schematic of the mechanisms behind shRNA knockdown, Cas9 knockout, and Cas9 
transcriptional activation. ShRNA knockdown begins with processing of the shRNA by 
Drosha/Dicer machinery and results in degradation of an RNA transcript with a 
complementary target site by the RNA-induced silencing complex (RISC). Cas9 knockout is 
accomplished by targeted indel formation at a genomic site complementary to the sgRNA. 
An indel can result in a frameshift, causing early termination, and either production of non-
functional protein or non-sense mediated decay (NMD) of the mRNA transcript. 
Programmable transcriptional activation can be achieved using dCas9 and activation 
domains (e.g. VP64/p65/HSF1) to recruit transcriptional machinery to the transcriptional 
start site of the desired gene target, resulting in upregulation of the target transcript. PAM, 
protospacer adjacent motif; NHEJ, non-homologous end joining; Pol II, RNA Polymerase II.
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Figure 2. Timeline and overview of experiments
Genome-scale Cas9 knockout and transcriptional activation screens begin with the 
construction of a plasmid library encoding the effector protein and sgRNAs. These plasmid 
libraries are packaged into lentivirus and then transduced into the cell type of interest to 
generate stably expressing lines for the screen, along with an accessory transcriptional 
activator complex (MS2-p65-HSF1) lentivirus for the case of activation screening. A 
selection pressure is applied depending on the nature of the screen and at given timepoints, 
genomic DNA is harvested. The sgRNA regions (colored bars) are amplified from genomic 
DNA and then analyzed by next generation sequencing followed by statistical analyses (e.g. 
RIGER) to identify candidate genes. Candidate genes are then validated by various forms of 
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analysis, including testing individual sgRNAs for the screening phenotype, indel formation 
by targeted sequencing, or transcript upregulation by qPCR.
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Figure 3. GeCKO and SAM libraries for genome-scale knockout and activation screens
(a) For knockout screening, the GeCKO v2 libraries target the 5′ conserved coding exons of 
19,050 human or 20,611 mouse coding genes with 6 sgRNAs per gene. (b) The GeCKO 
library is available in a 1 vector or 2 vector format. (c) For activation screening, the SAM 
libraries target the 200bp region upstream of the transcriptional start site of 23,430 human or 
23,439 mouse RefSeq coding isoforms with 3 sgRNAs per isoform. (d)The library has to be 
combined with additional SAM effectors in a 2 vector or 3 vector format. Both libraries 
select sgRNAs with minimal off-target activity.
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Figure 4. Anticipated results for genome-scale knockout and activation screens
We provide data from genome-scale knockout and activation screens for identifying drivers 
of resistance to the BRAF inhibitor vemurafenib (PLX) in a BRAFV600E (A375) melanoma 
cell line30,37. (a,b) Box plots showing the distribution of sgRNA frequencies after control 
(Veh, vehicle) or PLX treatment from n = 2 infection replicates. A significant number of 
guides are seen enriched and depleted in the PLX day 14 condition, revealing depletion of 
guides essential for cell growth and enrichment of guides that promote resistance to BRAF 
inhibitor. Boxes, 25th to 75th percentile; Whiskers, 1st to 99th percentile. (c,d) Scatterplot 
showing enrichment of sgRNAs targeting the top candidate genes identified by RIGER 
(colored dots) compared to other sgRNAs in the library (grey dots) after PLX treatment. 
Each gene has multiple sgRNAs that are enriched. Inset panel represents the entire dataset. 
Many of these genes are known tumor suppressors or oncogenes that play a role in PLX4720 
resistance. (e,f) The top hits of the screen are seen as distributed across the genome, 
revealing the necessity of genome-scale screens for identifying drivers of resistance. RIGER 
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P values for candidate enriched genes (colored dots) are significantly lower compared to 
other genes (grey dots) targeted by the sgRNA library.
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Table 1
Previously published screens using Cas9.
Type of screen Selection Organism Cas9 variant Reference
Knockout Vemurafenib resistance (positive) In vitro; A375 (human melanoma 
cell line)
Wild-type Cas9 37
Knockout 6-thioguanine/etoposide resistance 
(positive); gene essentiality (negative)
In vitro; HL60, KBM70 (human 
leukemic cell line)
Wild-type Cas9 38
Knockout 6-thioguanine/Clostridium septicum alpha-
toxin resistance (positive)
In vitro; mouse embryonic stem 
cells
Wild-type Cas9 39
Knockout Anthrax/diphtheria toxin resistance (positive) In vitro; HeLa (human 
adenocarcinoma cell line)
Wild-type Cas9 40
Knockout Surface receptor expression (negative) In vitro; EL4 (mouse thymic cell 
line) and MOLM13/NB4/TF1 
(human acute myeloid leukemia 
cell lines)
Wild-type Cas9 41
Knockout Metastasis (positive) In vivo; mouse Wild-type Cas9 42
Knockout Chromatin regulatory domain dependence 
(negative)
In vitro; RN2 (murine acute 
myeloid leukemia cell line)
Wild-type Cas9 43
Knockout Bacterial lipopolysaccharide response 
(marker gene)
Ex vivo; bone-marrow derived 
dendritic cells (mouse)
Wild-type Cas9 44
Knockout Fetal hemoglobin regulation by BCL11A 
enhancer (marker gene)
In vitro; HUDEP-2 (human 
erythroid progenitor cell line)
Wild-type Cas9 53
Knockout Gene dependency for essential genes 
(negative)
In vitro; KBM7 (human chronic 
myelogenous leukemia cell line)
Wild-type Cas9 45
Knockout p53 binding sites (positive); ESR1 binding 
sites (negative)
In vitro; BJ (human fibroblast cell 
line); MCF-7, T47D, and MDA-
MB-231 (human breast cancer cell 
line)
Wild-type Cas9 54
Knockout POU5F1 regulation (marker gene) In vitro; H1(human embryonic 
stem cell line)
Wild-type Cas9 55
Knockout Combinatorial gene dependency (negative) In vitro; OVCAR8-ADR (human 
ovarian cancer cell line)
Wild-type Cas9 46
Knockout Vemurafenib resistance (positive); essential 
genes (negative); 6-thioguanine resistance 
(positive); interferon survival (positive)
In vitro; A375 (human melanoma 
cell line); HT29 (human colorectal 
adenocarcinoma cell line); 
HEK293T (human embryonic 
kidney cell line); BV2 (mouse cell 
line)
Wild-type Cas9 47
Knockout Survival under oxidative stress (positive) In vitro; K562 (human leukemic 
cell line)
Wild-type Cas9 48
Knockout Dengue virus resistance/Hepatitis C virus 
resistance
In vitro; Huh7.5.1 (human 
hepatocyte cell line)
Wild-type Cas9 49
Knockout West Nile virus resistance In vitro; 293T (human embryonic 
kidney cell line)
Wild-type Cas9 50
Knockout Type III secretion system resistance In vitro; HT29 (human colorectal 
adenocarcinoma cell line)
Wild-type Cas9 51
Knockout Norovirus resistance In vitro; BV2 (mouse microglial 
cells)
Wild-type Cas9 52
Knockout CUL3 regulation and Vemurafenib resistance 
(positive)
In vitro; A375 (human melanoma 
cell line)
Wild-type Cas9 56
Activation Ricin sensitivity (both); cell growth (both) In vitro; K562 (human leukemic 
cell line)
sunCas9-VP64 28
Activation Vemurafenib resistance (positive) In vitro; A375 (human melanoma 
cell line)
dCas9-VP64/P65/HSF1 30
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Type of screen Selection Organism Cas9 variant Reference
Knockdown Ricin resistance (positive)/essential genes 
(negative)/cholera sensitivity (both)
In vitro; K562 (human leukemic 
cell line)
dCas9 or dCas9-KRAB 28
Knockdown Gene essentiality In vitro; K562 (human leukemic 
cell line)
KRAB-dCas9 57
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Table 2
Primers for amplifying the sgRNA oligo library.
Primer Sequence (5′–3′) Purpose
Oligo-Fwd GTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACC Targeted 
knockout or 
activation library 
cloning
Oligo-Knockout-Rev ACTTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAAC Targeted 
knockout library 
cloning
Oligo-Activation-Rev ATTTTAACTTGCTAGGCCCTGCAGACATGGGTGATCCTCATGTTGGCCTAGCTCTAAAAC Targeted 
activation library 
cloning
Nat Protoc. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Joung et al. Page 65
Ta
bl
e 
3
Pr
im
er
 se
qu
en
ce
s f
or
 a
m
pl
ify
in
g 
sg
RN
A
 li
br
ar
y 
an
d 
N
G
S.
 T
he
 1
0 
di
ffe
re
nt
 N
G
S-
Li
b-
Fw
d 
pr
im
er
s e
ac
h 
co
nt
ai
n 
1–
10
 a
dd
iti
on
al
 n
uc
le
ot
id
es
 a
fte
r t
he
 Il
lu
m
in
a 
Re
ad
 1
 S
eq
ue
nc
in
g 
pr
im
er
 d
es
ig
ne
d 
to
 in
cr
ea
se
 
th
e 
di
v
er
sit
y 
of
 th
e 
N
G
S 
lib
ra
ry
.
 
A
ll 
10
 N
G
S-
Li
b-
Fw
d 
pr
im
er
s a
re
 re
qu
ire
d 
w
he
n 
am
pl
ify
in
g 
sg
RN
A
 li
br
ar
y 
fo
r N
G
S.
 T
he
 8
 N
G
S-
Li
b-
Re
v
 p
rim
er
s p
ro
v
id
e 
un
iq
ue
 b
ar
co
de
s (
bo
ld)
 fo
r d
ist
ing
uis
hin
g d
iff
er
en
t 
sg
RN
A
 li
br
ar
ie
s (
e.g
. e
x
pe
rim
en
ta
l a
nd
 c
on
tro
l c
on
di
tio
ns
 fo
r 4
 sc
re
en
in
g 
bi
or
ep
s) 
in 
a p
oo
led
 se
qu
en
cin
g r
un
, a
nd
 th
e n
um
be
r o
f N
GS
-L
ib-
Re
v
 p
rim
er
s n
ee
de
d 
de
pe
nd
s o
n 
th
e 
nu
m
be
r o
f d
iff
er
en
t s
gR
N
A
 
lib
ra
rie
s t
o 
be
 se
qu
en
ce
d 
to
ge
th
er
 in
 a
 p
oo
le
d 
ru
n.
 S
in
ce
 th
e 
sg
RN
A
 b
ac
kb
on
e 
is 
di
ffe
re
nt
 b
et
w
ee
n 
th
e 
G
eC
KO
 a
nd
 S
A
M
 li
br
ar
ie
s, 
se
pa
ra
te
 N
G
S-
Li
b-
KO
-R
ev
 a
n
d 
N
G
S-
Li
b-
SA
M
-R
ev
 p
rim
er
s h
av
e 
be
en
 
pr
ov
id
ed
 fo
r e
ac
h 
lib
ra
ry
.
Pr
im
er
Se
qu
en
ce
 (5
′–3
′)
Pu
rp
os
e
N
G
S-
Li
b-
Fw
d-
1
A
AT
G
AT
A
CG
G
CG
AC
CA
CC
G
AG
AT
CT
A
CA
CT
CT
TT
CC
CT
A
CA
CG
AC
G
CT
CT
TC
CG
AT
CT
TA
A
G
TA
G
AG
G
CT
TT
AT
AT
AT
CT
TG
TG
G
A
A
AG
G
AC
G
A
A
AC
AC
C
G
eC
K
O
 o
r S
A
M
 sg
RN
A
 li
br
ar
y 
N
G
S
N
G
S-
Li
b-
Fw
d-
2
A
AT
G
AT
A
CG
G
CG
AC
CA
CC
G
AG
AT
CT
A
CA
CT
CT
TT
CC
CT
A
CA
CG
AC
G
CT
CT
TC
CG
AT
CT
AT
CA
TG
CT
TA
G
CT
TT
AT
AT
AT
CT
TG
TG
G
A
A
AG
G
AC
G
A
A
AC
AC
C
G
eC
K
O
 o
r S
A
M
 sg
RN
A
 li
br
ar
y 
N
G
S
N
G
S-
Li
b-
Fw
d-
3
A
AT
G
AT
A
CG
G
CG
AC
CA
CC
G
AG
AT
CT
A
CA
CT
CT
TT
CC
CT
A
CA
CG
AC
G
CT
CT
TC
CG
AT
CT
G
AT
G
CA
CA
TC
TG
CT
TT
AT
AT
AT
CT
TG
TG
G
A
A
AG
G
AC
G
A
A
AC
AC
C
G
eC
K
O
 o
r S
A
M
 sg
RN
A
 li
br
ar
y 
N
G
S
N
G
S-
Li
b-
Fw
d-
4
A
AT
G
AT
A
CG
G
CG
AC
CA
CC
G
AG
AT
CT
A
CA
CT
CT
TT
CC
CT
A
CA
CG
AC
G
CT
CT
TC
CG
AT
CT
CG
AT
TG
CT
CG
AC
G
CT
TT
AT
AT
AT
CT
TG
TG
G
A
A
AG
G
AC
G
A
A
AC
AC
C
G
eC
K
O
 o
r S
A
M
 sg
RN
A
 li
br
ar
y 
N
G
S
N
G
S-
Li
b-
Fw
d-
5
A
AT
G
AT
A
CG
G
CG
AC
CA
CC
G
AG
AT
CT
A
CA
CT
CT
TT
CC
CT
A
CA
CG
AC
G
CT
CT
TC
CG
AT
CT
TC
G
AT
A
G
CA
AT
TC
G
CT
TT
AT
AT
AT
CT
TG
TG
G
A
A
AG
G
AC
G
A
A
AC
AC
C
G
eC
K
O
 o
r S
A
M
 sg
RN
A
 li
br
ar
y 
N
G
S
N
G
S-
Li
b-
Fw
d-
6
A
AT
G
AT
A
CG
G
CG
AC
CA
CC
G
AG
AT
CT
A
CA
CT
CT
TT
CC
CT
A
CA
CG
AC
G
CT
CT
TC
CG
AT
CT
AT
CG
AT
A
G
TT
G
CT
TG
CT
TT
AT
AT
AT
CT
TG
TG
G
A
A
AG
G
AC
G
A
A
AC
AC
C
G
eC
K
O
 o
r S
A
M
 sg
RN
A
 li
br
ar
y 
N
G
S
N
G
S-
Li
b-
Fw
d-
7
A
AT
G
AT
A
CG
G
CG
AC
CA
CC
G
AG
AT
CT
A
CA
CT
CT
TT
CC
CT
A
CA
CG
AC
G
CT
CT
TC
CG
AT
CT
G
AT
CG
AT
CC
AG
TT
A
G
G
CT
TT
AT
AT
AT
CT
TG
TG
G
A
A
AG
G
AC
G
A
A
AC
AC
C
G
eC
K
O
 o
r S
A
M
 sg
RN
A
 li
br
ar
y 
N
G
S
N
G
S-
Li
b-
Fw
d-
8
A
AT
G
AT
A
CG
G
CG
AC
CA
CC
G
AG
AT
CT
A
CA
CT
CT
TT
CC
CT
A
CA
CG
AC
G
CT
CT
TC
CG
AT
CT
CG
AT
CG
AT
TT
G
AG
CC
TG
CT
TT
AT
AT
AT
CT
TG
TG
G
A
A
AG
G
AC
G
A
A
AC
AC
C
G
eC
K
O
 o
r S
A
M
 sg
RN
A
 li
br
ar
y 
N
G
S
N
G
S-
Li
b-
Fw
d-
9
A
AT
G
AT
A
CG
G
CG
AC
CA
CC
G
AG
AT
CT
A
CA
CT
CT
TT
CC
CT
A
CA
CG
AC
G
CT
CT
TC
CG
AT
CT
A
CG
AT
CG
AT
A
CA
CG
AT
CG
CT
TT
AT
AT
AT
CT
TG
TG
G
A
A
AG
G
AC
G
A
A
AC
AC
C
G
eC
K
O
 o
r S
A
M
 sg
RN
A
 li
br
ar
y 
N
G
S
N
G
S-
Li
b-
Fw
d-
10
A
AT
G
AT
A
CG
G
CG
AC
CA
CC
G
AG
AT
CT
A
CA
CT
CT
TT
CC
CT
A
CA
CG
AC
G
CT
CT
TC
CG
AT
CT
TA
CG
AT
CG
AT
G
G
TC
CA
G
AG
CT
TT
AT
AT
AT
CT
TG
TG
G
A
A
AG
G
AC
G
A
A
AC
AC
C
G
eC
K
O
 o
r S
A
M
 sg
RN
A
 li
br
ar
y 
N
G
S
N
G
S-
Li
b-
KO
-R
ev
-1
CA
AG
CA
G
A
AG
AC
G
G
CA
TA
CG
AG
AT
TC
G
C
C
TT
G
G
TG
AC
TG
G
AG
TT
CA
G
AC
G
TG
TG
CT
CT
TC
CG
AT
CT
CC
G
AC
TC
G
G
TG
CC
AC
TT
TT
TC
A
A
G
eC
K
O
 sg
RN
A
 li
br
ar
y 
N
G
S 
an
d 
ba
rc
od
e 
(bo
ld)
N
G
S-
Li
b-
KO
-R
ev
-2
CA
AG
CA
G
A
AG
AC
G
G
CA
TA
CG
AG
AT
AT
AG
C
G
TC
G
TG
AC
TG
G
AG
TT
CA
G
AC
G
TG
TG
CT
CT
TC
CG
AT
CT
CC
G
AC
TC
G
G
TG
CC
AC
TT
TT
TC
A
A
G
eC
K
O
 sg
RN
A
 li
br
ar
y 
N
G
S 
an
d 
ba
rc
od
e 
(bo
ld)
N
G
S-
Li
b-
KO
-R
ev
-3
CA
AG
CA
G
A
AG
AC
G
G
CA
TA
CG
AG
AT
G
A
AG
A
AG
TG
TG
AC
TG
G
AG
TT
CA
G
AC
G
TG
TG
CT
CT
TC
CG
AT
CT
CC
G
AC
TC
G
G
TG
CC
AC
TT
TT
TC
A
A
G
eC
K
O
 sg
RN
A
 li
br
ar
y 
N
G
S 
an
d 
ba
rc
od
e 
(bo
ld)
N
G
S-
Li
b-
KO
-R
ev
-4
CA
AG
CA
G
A
AG
AC
G
G
CA
TA
CG
AG
AT
AT
TC
TA
G
G
G
TG
AC
TG
G
AG
TT
CA
G
AC
G
TG
TG
CT
CT
TC
CG
AT
CT
CC
G
AC
TC
G
G
TG
CC
AC
TT
TT
TC
A
A
G
eC
K
O
 sg
RN
A
 li
br
ar
y 
N
G
S 
an
d 
ba
rc
od
e 
(bo
ld)
N
G
S-
Li
b-
KO
-R
ev
-5
CA
AG
CA
G
A
AG
AC
G
G
CA
TA
CG
AG
AT
C
G
TT
AC
C
A
G
TG
AC
TG
G
AG
TT
CA
G
AC
G
TG
TG
CT
CT
TC
CG
AT
CT
CC
G
AC
TC
G
G
TG
CC
AC
TT
TT
TC
A
A
G
eC
K
O
 sg
RN
A
 li
br
ar
y 
N
G
S 
an
d 
ba
rc
od
e 
(bo
ld)
N
G
S-
Li
b-
KO
-R
ev
-6
CA
AG
CA
G
A
AG
AC
G
G
CA
TA
CG
AG
AT
G
TC
TG
AT
G
G
TG
AC
TG
G
AG
TT
CA
G
AC
G
TG
TG
CT
CT
TC
CG
AT
CT
CC
G
AC
TC
G
G
TG
CC
AC
TT
TT
TC
A
A
G
eC
K
O
 sg
RN
A
 li
br
ar
y 
N
G
S 
an
d 
ba
rc
od
e 
(bo
ld)
N
G
S-
Li
b-
KO
-R
ev
-7
CA
AG
CA
G
A
AG
AC
G
G
CA
TA
CG
AG
AT
TT
AC
G
C
AC
G
TG
AC
TG
G
AG
TT
CA
G
AC
G
TG
TG
CT
CT
TC
CG
AT
CT
CC
G
AC
TC
G
G
TG
CC
AC
TT
TT
TC
A
A
G
eC
K
O
 sg
RN
A
 li
br
ar
y 
N
G
S 
an
d 
ba
rc
od
e 
(bo
ld)
N
G
S-
Li
b-
KO
-R
ev
-8
CA
AG
CA
G
A
AG
AC
G
G
CA
TA
CG
AG
AT
TT
G
A
AT
AG
G
TG
AC
TG
G
AG
TT
CA
G
AC
G
TG
TG
CT
CT
TC
CG
AT
CT
CC
G
AC
TC
G
G
TG
CC
AC
TT
TT
TC
A
A
G
eC
K
O
 sg
RN
A
 li
br
ar
y 
N
G
S 
an
d 
ba
rc
od
e 
(bo
ld)
N
G
S-
Li
b-
SA
M
-R
ev
-1
CA
AG
CA
G
A
AG
AC
G
G
CA
TA
CG
AG
AT
TC
G
C
C
TT
G
G
TG
AC
TG
G
AG
TT
CA
G
AC
G
TG
TG
CT
CT
TC
CG
AT
CT
G
CC
A
AG
TT
G
AT
A
A
CG
G
AC
TA
G
CC
TT
SA
M
 sg
RN
A
 li
br
ar
y 
N
G
S 
an
d 
ba
rc
od
e 
(bo
ld)
N
G
S-
Li
b-
SA
M
-R
ev
-2
CA
AG
CA
G
A
AG
AC
G
G
CA
TA
CG
AG
AT
AT
AG
C
G
TC
G
TG
AC
TG
G
AG
TT
CA
G
AC
G
TG
TG
CT
CT
TC
CG
AT
CT
G
CC
A
AG
TT
G
AT
A
A
CG
G
AC
TA
G
CC
TT
SA
M
 sg
RN
A
 li
br
ar
y 
N
G
S 
an
d 
ba
rc
od
e 
(bo
ld)
N
G
S-
Li
b-
SA
M
-R
ev
-3
CA
AG
CA
G
A
AG
AC
G
G
CA
TA
CG
AG
AT
G
A
AG
A
AG
TG
TG
AC
TG
G
AG
TT
CA
G
AC
G
TG
TG
CT
CT
TC
CG
AT
CT
G
CC
A
AG
TT
G
AT
A
A
CG
G
AC
TA
G
CC
TT
SA
M
 sg
RN
A
 li
br
ar
y 
N
G
S 
an
d 
ba
rc
od
e 
(bo
ld)
N
G
S-
Li
b-
SA
M
-R
ev
-4
CA
AG
CA
G
A
AG
AC
G
G
CA
TA
CG
AG
AT
AT
TC
TA
G
G
G
TG
AC
TG
G
AG
TT
CA
G
AC
G
TG
TG
CT
CT
TC
CG
AT
CT
G
CC
A
AG
TT
G
AT
A
A
CG
G
AC
TA
G
CC
TT
SA
M
 sg
RN
A
 li
br
ar
y 
N
G
S 
an
d 
ba
rc
od
e 
(bo
ld)
N
G
S-
Li
b-
SA
M
-R
ev
-5
CA
AG
CA
G
A
AG
AC
G
G
CA
TA
CG
AG
AT
C
G
TT
AC
C
A
G
TG
AC
TG
G
AG
TT
CA
G
AC
G
TG
TG
CT
CT
TC
CG
AT
CT
G
CC
A
AG
TT
G
AT
A
A
CG
G
AC
TA
G
CC
TT
SA
M
 sg
RN
A
 li
br
ar
y 
N
G
S 
an
d 
ba
rc
od
e 
(bo
ld)
N
G
S-
Li
b-
SA
M
-R
ev
-6
CA
AG
CA
G
A
AG
AC
G
G
CA
TA
CG
AG
AT
G
TC
TG
AT
G
G
TG
AC
TG
G
AG
TT
CA
G
AC
G
TG
TG
CT
CT
TC
CG
AT
CT
G
CC
A
AG
TT
G
AT
A
A
CG
G
AC
TA
G
CC
TT
SA
M
 sg
RN
A
 li
br
ar
y 
N
G
S 
an
d 
ba
rc
od
e 
(bo
ld)
Nat Protoc. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Joung et al. Page 66
Pr
im
er
Se
qu
en
ce
 (5
′–3
′)
Pu
rp
os
e
N
G
S-
Li
b-
SA
M
-R
ev
-7
CA
AG
CA
G
A
AG
AC
G
G
CA
TA
CG
AG
AT
TT
AC
G
C
AC
G
TG
AC
TG
G
AG
TT
CA
G
AC
G
TG
TG
CT
CT
TC
CG
AT
CT
G
CC
A
AG
TT
G
AT
A
A
CG
G
AC
TA
G
CC
TT
SA
M
 sg
RN
A
 li
br
ar
y 
N
G
S 
an
d 
ba
rc
od
e 
(bo
ld)
N
G
S-
Li
b-
SA
M
-R
ev
-8
CA
AG
CA
G
A
AG
AC
G
G
CA
TA
CG
AG
AT
TT
G
A
AT
AG
G
TG
AC
TG
G
AG
TT
CA
G
AC
G
TG
TG
CT
CT
TC
CG
AT
CT
G
CC
A
AG
TT
G
AT
A
A
CG
G
AC
TA
G
CC
TT
SA
M
 sg
RN
A
 li
br
ar
y 
N
G
S 
an
d 
ba
rc
od
e 
(bo
ld)
Nat Protoc. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Joung et al. Page 67
Table 4
Primers for amplifying target sites to determine percentage of indels by NGS. The custom first round primer 
consists of a universal sequence followed by an optional stagger sequence (1–10 additional random 
nucleotides for introducing diversity in low-diversity NGS libraries) and the custom priming site designed to 
amplify the 100–300bp region centered around the sgRNA cut site. Second round universal, barcoded primers 
amplify the first round PCR products. We have provided 8 Fwd and 12 Rev second round primers, each with 
unique barcodes (bold) to provide for a total of 96 different combinations when sequencing indels in a pooled 
NGS run.
Primer Sequence (5′–3′) Purpose
NGS-indel-R1-Fwd CTTTCCCTACACGACGCTCTTCCGATCT(stagger)[priming_site] Custom first 
round 
amplification 
for NGS
NGS-indel-R1-Rev GACTGGAGTTCAGACGTGTGCTCTTCCGATCT[priming_site] Custom first 
round 
amplification 
for NGS
NGS-indel-R2-Fwd-1 AATGATACGGCGACCACCGAGATCTACACTATAGCCTACACTCTTTCCCTACACGACGCTCTTCC Universal 
second 
round 
amplification 
for NGS
NGS-indel-R2-Fwd-2 AATGATACGGCGACCACCGAGATCTACACATAGAGGCACACTCTTTCCCTACACGACGCTCTTCC Universal 
second 
round 
amplification 
for NGS
NGS-indel-R2-Fwd-3 AATGATACGGCGACCACCGAGATCTACACCCTATCCTACACTCTTTCCCTACACGACGCTCTTCC Universal 
second 
round 
amplification 
for NGS
NGS-indel-R2-Fwd-4 AATGATACGGCGACCACCGAGATCTACACGGCTCTGAACACTCTTTCCCTACACGACGCTCTTCC Universal 
second 
round 
amplification 
for NGS
NGS-indel-R2-Fwd-5 AATGATACGGCGACCACCGAGATCTACACAGGCGAAGACACTCTTTCCCTACACGACGCTCTTCC Universal 
second 
round 
amplification 
for NGS
NGS-indel-R2-Fwd-6 AATGATACGGCGACCACCGAGATCTACACTAATCTTAACACTCTTTCCCTACACGACGCTCTTCC Universal 
second 
round 
amplification 
for NGS
NGS-indel-R2-Fwd-7 AATGATACGGCGACCACCGAGATCTACACCAGGACGTACACTCTTTCCCTACACGACGCTCTTCC Universal 
second 
round 
amplification 
for NGS
NGS-indel-R2-Fwd-8 AATGATACGGCGACCACCGAGATCTACACGTACTGACACACTCTTTCCCTACACGACGCTCTTCC Universal 
second 
round 
amplification 
for NGS
NGS-indel-R2-Rev-1 CAAGCAGAAGACGGCATACGAGATCGAGTAATGTGACTGGAGTTCAGACGTGTGCTCTTC Universal 
second 
round 
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Primer Sequence (5′–3′) Purpose
amplification 
for NGS
NGS-indel-R2-Rev-2 CAAGCAGAAGACGGCATACGAGATTCTCCGGAGTGACTGGAGTTCAGACGTGTGCTCTTC Universal 
second 
round 
amplification 
for NGS
NGS-indel-R2-Rev-3 CAAGCAGAAGACGGCATACGAGATAATGAGCGGTGACTGGAGTTCAGACGTGTGCTCTTC Universal 
second 
round 
amplification 
for NGS
NGS-indel-R2-Rev-4 CAAGCAGAAGACGGCATACGAGATGGAATCTCGTGACTGGAGTTCAGACGTGTGCTCTTC Universal 
second 
round 
amplification 
for NGS
NGS-indel-R2-Rev-5 CAAGCAGAAGACGGCATACGAGATTTCTGAATGTGACTGGAGTTCAGACGTGTGCTCTTC Universal 
second 
round 
amplification 
for NGS
NGS-indel-R2-Rev-6 CAAGCAGAAGACGGCATACGAGATACGAATTCGTGACTGGAGTTCAGACGTGTGCTCTTC Universal 
second 
round 
amplification 
for NGS
NGS-indel-R2-Rev-7 CAAGCAGAAGACGGCATACGAGATAGCTTCAGGTGACTGGAGTTCAGACGTGTGCTCTTC Universal 
second 
round 
amplification 
for NGS
NGS-indel-R2-Rev-8 CAAGCAGAAGACGGCATACGAGATGCGCATTAGTGACTGGAGTTCAGACGTGTGCTCTTC Universal 
second 
round 
amplification 
for NGS
NGS-indel-R2-Rev-9 CAAGCAGAAGACGGCATACGAGATCATAGCCGGTGACTGGAGTTCAGACGTGTGCTCTTC Universal 
second 
round 
amplification 
for NGS
NGS-indel-R2-Rev-10 CAAGCAGAAGACGGCATACGAGATTTCGCGGAGTGACTGGAGTTCAGACGTGTGCTCTTC Universal 
second 
round 
amplification 
for NGS
NGS-indel-R2-Rev-11 CAAGCAGAAGACGGCATACGAGATGCGCGAGAGTGACTGGAGTTCAGACGTGTGCTCTTC Universal 
second 
round 
amplification 
for NGS
NGS-indel-R2-Rev-12 CAAGCAGAAGACGGCATACGAGATCTATCGCTGTGACTGGAGTTCAGACGTGTGCTCTTC Universal 
second 
round 
amplification 
for NGS
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Table 5
Primers for sgRNA cloning and validation.
Primer Sequence (5′-3′) Purpose
sgRNA-top CACCgNNNNNNNNNNNNNNNNNNNN Top strand primer for cloning sgRNA into sgRNA library backbone; 
appended guanine in lowercase
sgRNA-bottom AAACNNNNNNNNNNNNNNNNNNNNc Bottom strand primer for cloning sgRNA into sgRNA library backbone; 
appended cytosine in lowercase
NT1-top CACCGCTGAAAAAGGAAGGAGTTGA Top strand primer for cloning non-targetting sgRNA into sgRNA library 
backbone
NT1-bottom AAACTCAACTCCTTCCTTTTTCAGC Bottom strand primer for cloning non-targetting sgRNA into sgRNA 
library backbone
NT2-top CACCGAAGATGAAAGGAAAGGCGTT Top strand primer for cloning non-targetting sgRNA into sgRNA library 
backbone
NT2-bottom AAACAACGCCTTTCCTTTCATCTTC Bottom strand primer for cloning non-targetting sgRNA into sgRNA 
library backbone
U6-Fwd CGTGACGTAGAAAGTAATAATTTCTTGGG Sanger sequencing of sgRNA cloned into sgRNA library backbone
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Table 6
Troubleshooting table.
Step Problem Possible reason Possible solution
26 Insufficient number of 
colonies
Inefficient electroporation; plates dried out 
during bacteria spreading; salt 
contamination or low concentration of DNA 
for electroporation (custom library only).
Increase number of electroporations if feasible; follow the 
manufacturer’s instructions for optimal efficiency (i.e. 
ensure cuvettes, tubes and cells are chilled thoroughly and 
recovery media is added immediately after 
electroporation); spread bacterial suspension evenly 
without letting plates dry; limit plate warming to <2h and 
add 1 volume of additional LB media before spreading as 
recommended; if the DNA for electroporation has a 
260/230 ratio <1.8 or is <50 ng μl−1 by NanoDrop, 
consider re-prepping (custom library only).
27 Colonies growing on 
negative control plate
Incomplete digestion of library plasmid 
backbone
Increase the amount of restriction enzyme and 
phosphatase, ensure added DTT is fresh and stored at 
−20 °C as recommended
39 Less than 70% of 
perfectly matched 
sgRNAs
NGS reads are low quality; Incorrect flag 
for presence of ‘G’ before guide spacer 
sequence; Low oligo synthesis quality 
(custom library only)
If <75% of clusters passed filter, consider resequencing the 
library with more optimal cluster density and cluster 
passing filter; Check for the proper flag indicating 
presence of ‘G’; if both the negative gibson control and 
sequencing quality were good, contact your synthesis 
company or core to discuss your results
39 More than 0.5% of 
sgRNAs are undetected
Insufficient colonies during amplification 
process; Not enough cloning reactions 
during custom sgRNA library cloning
Increase the number of electroporations; scale up the 
number of reactions throughout cloning
39 Skew ratio of custom 
sgRNA library is greater 
than 10
Insufficient representation and potential bias 
during cloning process; Low oligo synthesis 
quality (custom library only)
Reduce the number of PCR cycles during oligo 
amplification; increase the number of reactions throughout 
cloning, ensure >500 colonies per guide during library 
amplification; contact your synthesis company or core to 
discuss your results.
51 Low survival following 
Lipofectamine 
transfection
Cell density at transfection <75%; failure to 
replace media within 6 h post transfection
Ensure even plating and a cell density of 80–90% during 
transfection. Replace media 4 h after transfection. The cell 
density should not be <80% at the time of lentivirus 
harvest.
51 Low Lipofectamine 
transfection efficiency
Incorrect amount or poor quality DNA used 
for transfection; poorly or unevenly seeded 
cells
Use low-passage-number cells (passage number <10) and 
do not let cells reach >90% confluency; reseed cells evenly 
at recommended density; prepare new DNA for 
transfection
53 Significant cell survival 
in the no virus, 
antibiotic-selected 
control
Incorrect antibiotic concentration Construct a kill curve for the antibiotic and cell line of 
interest by titrating different concentrations of the 
antibiotic on cells seeded at 10% confluency. Choose the 
lowest concentration that kills all cells after 4–7 days. 
When using zeocin, only 90–95% of cells may be killed at 
the optimal concentration after 7 days, but this should not 
interfere with screening when using zeocin for selection of 
SAM sgRNAs.
53 Low lentivirus titer Low lentivirus production or transduction 
efficiency
Concentrate the lentivirus using Amicon Ultra-15 
Centrifugal Filter Unit with Ultracel-100 membrane or 
ultracentrifugation at 88,000 × g for 2 h at 4 °C. Discard 
the supernatant and resuspend the lentivirus in cold PBS at 
4 °C overnight.
58 No amplification of 
gDNA
Incorrect template or primer; incorrect 
template or primer concentration
Use appropriate NGS-Rev primer corresponding to the 
screen; titrate gDNA concentration to 1–3 μg for a 50 μl 
reaction; titrate primer concentration to a final 
concentration of 0.1–0.5 μM
58 Primer dimer after gDNA 
amplification
Insufficient number of PCR cycles Increase the number of cycles for PCR up to 25; lower 
gDNA input and perform more reactions
76 Very few or no colonies 
on plates
Incorrect template; Low transformation 
efficiency
Use an appropriate antibiotic for the resistance marker on 
the plasmid backbone; verify competency of E. coli
80 Low percentage of 
correctly cloned sgRNAs
Incorrect template or primer; incorrect 
Golden Gate Assembly reaction
Check that the primer design is correct and that the top and 
bottom strands are complementary; verify restriction 
enzyme site on plasmid backbone; ensure use of the 
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Step Problem Possible reason Possible solution
suggested restriction enzyme (Fermentas Fast Digest) and 
DNA ligase (Enzymatics T7 ligase)
94 Multiple bands or no 
amplification during 
indel analysis
Inefficient or nonspecific priming; incorrect 
template concentration
Test different annealing temperatures (58–62 °C); re-
design primers to minimize primer dimer formation or 
nonspecific amplification; test a different high fidelity 
DNA polymerase; vary the magnesium concentration in 
the reaction. If none of the above steps solve the issue it 
may be helpful to clean up the Quickextract gDNA using 
Ampure beads to provide a cleaner PCR template.
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